-
1
-
-
0026076377
-
The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas
-
1 Quigley M. R. and Maroon J. C. (1991) The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 29: 385-388
-
(1991)
Neurosurgery
, vol.29
, pp. 385-388
-
-
Quigley, M.R.1
Maroon, J.C.2
-
2
-
-
0030859359
-
Chemotherapy of human malignant glioma: Prevention of efficacy by dexamethasone?
-
2 Weller M., Schmidt C., Roth W. and Dichgans J. (1997) Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology 48: 1704-1709
-
(1997)
Neurology
, vol.48
, pp. 1704-1709
-
-
Weller, M.1
Schmidt, C.2
Roth, W.3
Dichgans, J.4
-
3
-
-
0032563826
-
Dexamethasone-mediated protection from drug cytotoxicity: Association with p21WAF1/CIP1 protein accumulation?
-
3 Naumann U., Durka S. and Weller M. (1998) Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation? Oncogene 17: 1567-1575
-
(1998)
Oncogene
, vol.17
, pp. 1567-1575
-
-
Naumann, U.1
Durka, S.2
Weller, M.3
-
4
-
-
0029841263
-
Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas
-
4 Kim L., Hochberg F. H., Thornton A. F., Harsh G. R. 4th, Patel H., Finkelstein D. et al. (1996) Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J. Neurosurg. 85: 602-607
-
(1996)
J. Neurosurg.
, vol.85
, pp. 602-607
-
-
Kim, L.1
Hochberg, F.H.2
Thornton, A.F.3
Harsh G.R. IV4
Patel, H.5
Finkelstein, D.6
-
5
-
-
0027972896
-
Chemotherapy for unaplastic oligodendroglioma
-
5 Cairncross G., Macdonald D., Ludwin S., Lee D., Cascino T., Buckner J, et al. (1994) Chemotherapy for unaplastic oligodendroglioma. J. Clin. Oncol. 12: 2013-2021
-
(1994)
J. Clin. Oncol.
, vol.12
, pp. 2013-2021
-
-
Cairncross, G.1
Macdonald, D.2
Ludwin, S.3
Lee, D.4
Cascino, T.5
Buckner, J.6
-
6
-
-
0026576153
-
Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas
-
6 Jeremic B., Jovanovic D., Djuric L. J., Jevremovic S. and Mijatovic L. J. (1992) Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas. J. Chemother. 4: 123-126
-
(1992)
J. Chemother.
, vol.4
, pp. 123-126
-
-
Jeremic, B.1
Jovanovic, D.2
Djuric, L.J.3
Jevremovic, S.4
Mijatovic, L.J.5
-
7
-
-
0025239917
-
Superiority of post-radiotherapyadjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report
-
7 Levin V. A., Silver P., Hannigan J., Wara W. M., Gutin P. H., Davis R. L. et al. (1990) Superiority of post-radiotherapyadjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int. J. Radiat. Oncol. Biol. Phys. 18: 321-324
-
(1990)
Int. J. Radiat. Oncol. Biol. Phys.
, vol.18
, pp. 321-324
-
-
Levin, V.A.1
Silver, P.2
Hannigan, J.3
Wara, W.M.4
Gutin, P.H.5
Davis, R.L.6
-
8
-
-
0028911680
-
Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas
-
8 Levin V. A., Prados M. R., Wara W. M., Davis R. L., Gutin P. H., Phillips T. L, et al. (1995) Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. Int. J. Radial. Oncol. Biol. Phys. 32: 75-83
-
(1995)
Int. J. Radial. Oncol. Biol. Phys.
, vol.32
, pp. 75-83
-
-
Levin, V.A.1
Prados, M.R.2
Wara, W.M.3
Davis, R.L.4
Gutin, P.H.5
Phillips, T.L.6
-
9
-
-
0027516695
-
Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
-
9 Fine H. A., Dear K. B., Loeffler J. S., Black P. M. and Canellos G. P. (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585-2597
-
(1993)
Cancer
, vol.71
, pp. 2585-2597
-
-
Fine, H.A.1
Dear, K.B.2
Loeffler, J.S.3
Black, P.M.A.4
Canellos, G.P.5
-
10
-
-
0024955830
-
The role of chemotherapy in the treatment of gliomas in adults
-
10 Stewart D. J. (1989) The role of chemotherapy in the treatment of gliomas in adults. Cancer Treat. Rev. 16: 129-160
-
(1989)
Cancer Treat. Rev.
, vol.16
, pp. 129-160
-
-
Stewart, D.J.1
-
11
-
-
0018125603
-
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial
-
11 Walker M. D., Alexander E. Jr, Hunt W. E., MacCarty C. S., Mahaley M. S. Jr, Mealey J. Jr et al. (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg. 49: 333-343
-
(1978)
J. Neurosurg.
, vol.49
, pp. 333-343
-
-
Walker, M.D.1
Alexander E., Jr.2
Hunt, W.E.3
MacCarty, C.S.4
Mahaley M.S., Jr.5
Mealey J., Jr.6
-
12
-
-
0027145640
-
Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: A phase II study
-
12 Ameri A., Poisson M., Chen Q. M. and Delattre J. Y. (1993) Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study. J. Neurooncol. 17: 43-46
-
(1993)
J. Neurooncol.
, vol.17
, pp. 43-46
-
-
Ameri, A.1
Poisson, M.2
Chen, Q.M.3
Delattre, J.Y.4
-
13
-
-
0031047440
-
Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: A phase II study
-
13 Ameri A., Poisson M., Chauveinc L., Chen Q. M. and Delattre J. Y. (1997) Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: a phase II study. J. Neurooncol. 32: 155-160
-
(1997)
J. Neurooncol.
, vol.32
, pp. 155-160
-
-
Ameri, A.1
Poisson, M.2
Chauveinc, L.3
Chen, Q.M.4
Delattre, J.Y.5
-
14
-
-
0030933487
-
Thiotepa and etoposide treatment of recurrent malignant gliomas: Phase I study
-
14 Balmaceda C., Fetell M. R. and Hesdorffer C. (1997) Thiotepa and etoposide treatment of recurrent malignant gliomas: phase I study. Cancer Chemother. Pharmacol. 40: 72-74
-
(1997)
Cancer Chemother. Pharmacol.
, vol.40
, pp. 72-74
-
-
Balmaceda, C.1
Fetell, M.R.2
Hesdorffer, C.3
-
15
-
-
0027071631
-
Carboplatin combined with carmustine and etoposide in the treatment of glioblastoma
-
15 Boiardi A., Silvani A., Milanesi I., Botturi M. and Broggi G. (1992) Carboplatin combined with carmustine and etoposide in the treatment of glioblastoma. Ital. J. Neurol. Sci. 13: 717-722
-
(1992)
Ital. J. Neurol. Sci.
, vol.13
, pp. 717-722
-
-
Boiardi, A.1
Silvani, A.2
Milanesi, I.3
Botturi, M.4
Broggi, G.5
-
16
-
-
0026536938
-
Efficacy of '8-drugs-in-one-day' combination in treatment of recurrent GBM patients
-
16 Boiardi A., Silvani A., Milanesi I., Broggi G. and Fariselli L. (1992) Efficacy of '8-drugs-in-one-day' combination in treatment of recurrent GBM patients. J. Neurooncol. 12: 153-158
-
(1992)
J. Neurooncol.
, vol.12
, pp. 153-158
-
-
Boiardi, A.1
Silvani, A.2
Milanesi, I.3
Broggi, G.4
Fariselli, L.5
-
17
-
-
0031964962
-
Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: A phase II study
-
17 Brandes A. A., Rigon A., Zampieri P., Ermani M., Carollo C., Altavilla G. et al. (1998) Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. Cancer 82: 355-361
-
(1998)
Cancer
, vol.82
, pp. 355-361
-
-
Brandes, A.A.1
Rigon, A.2
Zampieri, P.3
Ermani, M.4
Carollo, C.5
Altavilla, G.6
-
18
-
-
0028939248
-
Concurrent cisplatin therapy and iodine 125 brachytherapy for recurrent malignant brain tumors
-
18 Chamberlain M. C., Barba D., Kormanik P., Berson A. M., Saunders W. M. and Shea M. C. (1995) Concurrent cisplatin therapy and iodine 125 brachytherapy for recurrent malignant brain tumors. Arch. Neurol. 52: 162-167
-
(1995)
Arch. Neurol.
, vol.52
, pp. 162-167
-
-
Chamberlain, M.C.1
Barba, D.2
Kormanik, P.3
Berson, A.M.4
Saunders, W.M.5
Shea, M.C.6
-
19
-
-
0029166912
-
Salvage chemotherapy with paclitaxel for recurrent primary brain tumors
-
19 Chamberlain M. C. and Kormanik P. (1995) Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J. Clin. Oncol. 13: 2066-2071
-
(1995)
J. Clin. Oncol.
, vol.13
, pp. 2066-2071
-
-
Chamberlain, M.C.1
Kormanik, P.2
-
20
-
-
0027516406
-
Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas
-
20 Cvitkovic F. B., Haie-Meder C., Papadimitrakopoulou V., Armand J. P., Cioloca C., Maugis N, et al. (1993) Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas. J. Neurooncol. 15: 9-17
-
(1993)
J. Neurooncol.
, vol.15
, pp. 9-17
-
-
Cvitkovic, F.B.1
Haie-Meder, C.2
Papadimitrakopoulou, V.3
Armand, J.P.4
Cioloca, C.5
Maugis, N.6
-
21
-
-
0027175888
-
Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma
-
21 Dinapoli R. P., Brown L. D., Arusell R. M., Earle J. D., O'Fallon J. R., Buckner J. C. et al. (1993) Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J. Clin. Oncol. 11: 1316-1321
-
(1993)
J. Clin. Oncol.
, vol.11
, pp. 1316-1321
-
-
Dinapoli, R.P.1
Brown, L.D.2
Arusell, R.M.3
Earle, J.D.4
O'Fallon, J.R.5
Buckner, J.C.6
-
22
-
-
0027288999
-
A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: A southwest oncology group study
-
22 Eyre H. J., Crowley J. J., Townsend J. J., Eltringham J. R., Morantz R. A., Schulman S. F. et al. (1993) A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J. Neurosurg. 78: 909-914
-
(1993)
J. Neurosurg.
, vol.78
, pp. 909-914
-
-
Eyre, H.J.1
Crowley, J.J.2
Townsend, J.J.3
Eltringham, J.R.4
Morantz, R.A.5
Schulman, S.F.6
-
23
-
-
0030762796
-
Preirradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions
-
23 Fetell M. R., Grossman S. A., Fisher J. D., Erlanger B., Rowinsky E., Stockel J. et al. (1997) Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. J. Clin. Oncol. 15: 3121-3128
-
(1997)
J. Clin. Oncol.
, vol.15
, pp. 3121-3128
-
-
Fetell, M.R.1
Grossman, S.A.2
Fisher, J.D.3
Erlanger, B.4
Rowinsky, E.5
Stockel, J.6
-
24
-
-
0029800151
-
Phase II trial of docetaxel in patients with recurrent malignant glioma: A study of the National Cancer Institute of Canada Clinical Trials Group
-
24 Forsyth P., Cairncross G., Stewart D., Goodyear M., Wainman N. and Eisenhauer E. (1996) Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group. Invest. New Drugs 14: 203-206
-
(1996)
Invest. New Drugs
, vol.14
, pp. 203-206
-
-
Forsyth, P.1
Cairncross, G.2
Stewart, D.3
Goodyear, M.4
Wainman, N.5
Eisenhauer, E.6
-
25
-
-
0030053959
-
Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma
-
25 Fulton D., Urtasun R. and Forsyth P. (1996) Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J. Neurooncol. 27: 149-155
-
(1996)
J. Neurooncol.
, vol.27
, pp. 149-155
-
-
Fulton, D.1
Urtasun, R.2
Forsyth, P.3
-
26
-
-
0031692882
-
Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North central cancer treatment group results
-
26 Galanis E., Buckner J. C., Burch P. A., Schaefer P. L., Dinapoli R. P., Novotny P. J. et al. (1998) Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. J. Clin. Oncol. 16: 2953-2958
-
(1998)
J. Clin. Oncol.
, vol.16
, pp. 2953-2958
-
-
Galanis, E.1
Buckner, J.C.2
Burch, P.A.3
Schaefer, P.L.4
Dinapoli, R.P.5
Novotny, P.J.6
-
27
-
-
0030793974
-
Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma
-
27 Grossman S. A., Wharam M., Sheidler V., Kleinberg L., Zeltzman M., Yue N. et al. (1997) Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J. Clin. Oncol. 15: 2596-2603
-
(1997)
J. Clin. Oncol.
, vol.15
, pp. 2596-2603
-
-
Grossman, S.A.1
Wharam, M.2
Sheidler, V.3
Kleinberg, L.4
Zeltzman, M.5
Yue, N.6
-
28
-
-
0031818560
-
Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme
-
28 Gruber M. L., Glass J., Choudhri H. and Nirenberg A. (1998) Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme. Am. J. Clin. Oncol. 21: 338-340
-
(1998)
Am. J. Clin. Oncol.
, vol.21
, pp. 338-340
-
-
Gruber, M.L.1
Glass, J.2
Choudhri, H.3
Nirenberg, A.4
-
29
-
-
0027182175
-
An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors
-
29 Halperin E. C., Gaspar L., Imperato J., Salter M., Herndon J. 2nd and Dowling S. (1993) An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. Am. J. Clin. Oncol. 16: 277-283
-
(1993)
Am. J. Clin. Oncol.
, vol.16
, pp. 277-283
-
-
Halperin, E.C.1
Gaspar, L.2
Imperato, J.3
Salter, M.4
Herndon J. II5
Dowling, S.6
-
30
-
-
9044237687
-
A phase III randomized prospective trial of external beam radiotherapy. Mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain
-
30 Halperin E. C., Herndon J., Schold S. C., Brown M., Vick N., Cairncross J. G. et al. (1996) A phase III randomized prospective trial of external beam radiotherapy. mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. Int. J. Radiat. Oncol. Biol. Phys. 34: 793-802
-
(1996)
Int. J. Radiat. Oncol. Biol. Phys.
, vol.34
, pp. 793-802
-
-
Halperin, E.C.1
Herndon, J.2
Schold, S.C.3
Brown, M.4
Vick, N.5
Cairncross, J.G.6
-
31
-
-
0031882420
-
A therapeutic trial of radiation therapy with vincristine, etoposide, and procarbazine (VVP) in high grade intracranial gliomas an eastern cooperative oncology group study (E2392)
-
31 Hellman R., Neuberg D. S., Wagner H., Grunnet M., Robins H. I., Karp D. et al. (1998) A therapeutic trial of radiation therapy with vincristine, etoposide, and procarbazine (VVP) in high grade intracranial gliomas an Eastern Cooperative Oncology Group Study (E2392). J. Neurooncol. 37: 55-62
-
(1998)
J. Neurooncol.
, vol.37
, pp. 55-62
-
-
Hellman, R.1
Neuberg, D.S.2
Wagner, H.3
Grunnet, M.4
Robins, H.I.5
Karp, D.6
-
32
-
-
0031882610
-
Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine a phase-II study
-
32 Hildebrand J., De Witte O. and Sahmoud T. (1998) Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine a phase-II study. J. Neurooncol. 37: 155-160
-
(1998)
J. Neurooncol.
, vol.37
, pp. 155-160
-
-
Hildebrand, J.1
De Witte, O.2
Sahmoud, T.3
-
33
-
-
0029843617
-
Phase II study of DTIC, ACNU, and vincristine combination chemotherapy for supratentorial malignant astrocytomas
-
33 Ikeda J., Aida T., Sawamura Y., Abe H., Kaneko S., Kashiwaba T. et al. (1996) Phase II study of DTIC, ACNU, and vincristine combination chemotherapy for supratentorial malignant astrocytomas. Neurol. Med. Chir. Tokyo 36: 555-558
-
(1996)
Neurol. Med. Chir. Tokyo
, vol.36
, pp. 555-558
-
-
Ikeda, J.1
Aida, T.2
Sawamura, Y.3
Abe, H.4
Kaneko, S.5
Kashiwaba, T.6
-
34
-
-
0026650018
-
Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: A phase II study
-
34 Jeremie B., Grujicie D., Jevremovic S., Stanisavljevic B., Milojevic L., Djuric L. et al. (1992) Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J. Clin. Oncol. 10: 1074-1077
-
(1992)
J. Clin. Oncol.
, vol.10
, pp. 1074-1077
-
-
Jeremie, B.1
Grujicie, D.2
Jevremovic, S.3
Stanisavljevic, B.4
Milojevic, L.5
Djuric, L.6
-
35
-
-
0028138511
-
Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: A phase Ii study
-
35 Jeremie B., Grujicie D., Antunovic V., Djuric L., Stojanovic M. and Shibamoto Y. (1994) Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study. Int. J. Radiat. Oncol. Biol. Phys. 30: 1179-1185
-
(1994)
Int. J. Radiat. Oncol. Biol. Phys.
, vol.30
, pp. 1179-1185
-
-
Jeremie, B.1
Grujicie, D.2
Antunovic, V.3
Djuric, L.4
Stojanovic, M.5
Shibamoto, Y.6
-
36
-
-
0028867792
-
Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas
-
36 Kiu M. C., Chang C. N., Cheng W. C., Lin T. K., Wong C. W., Tang S. G. et al. (1995) Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas. J. Neurooncol. 25: 215-220
-
(1995)
J. Neurooncol.
, vol.25
, pp. 215-220
-
-
Kiu, M.C.1
Chang, C.N.2
Cheng, W.C.3
Lin, T.K.4
Wong, C.W.5
Tang, S.G.6
-
37
-
-
0029851979
-
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas
-
37 Kyritsis A. P., Yung W. K., Jaeckle K. A., Bruner J., Gleason M. J., Ictech S. E. et al. (1996) Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. Neurosurgery 39: 921-926
-
(1996)
Neurosurgery
, vol.39
, pp. 921-926
-
-
Kyritsis, A.P.1
Yung, W.K.2
Jaeckle, K.A.3
Bruner, J.4
Gleason, M.J.5
Ictech, S.E.6
-
38
-
-
0032005352
-
Fractionated stereotactic radiosurgery and concurrent taxol in recurrent glioblastoma multiforme: A preliminary report
-
38 Lederman G., Arbit E., Odaimi M., Lombardi E., Wrzolek M. and Wronski M. (1998) Fractionated stereotactic radiosurgery and concurrent taxol in recurrent glioblastoma multiforme: a preliminary report. Int. J. Radial. Oncol. Biol. Phys. 40: 661-666
-
(1998)
Int. J. Radial. Oncol. Biol. Phys.
, vol.40
, pp. 661-666
-
-
Lederman, G.1
Arbit, E.2
Odaimi, M.3
Lombardi, E.4
Wrzolek, M.5
Wronski, M.6
-
39
-
-
0026695162
-
Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance
-
39 Levin V. A. and Prados M. D. (1992) Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J. Clin. Oncol. 10: 766-771
-
(1992)
J. Clin. Oncol.
, vol.10
, pp. 766-771
-
-
Levin, V.A.1
Prados, M.D.2
-
40
-
-
0029161882
-
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme
-
40 Levin V. A., Maor M. H., Thall P. F., Yung W. K., Bruner J., Sawaya R. et al. (1995) Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 33: 357-364
-
(1995)
Int. J. Radiat. Oncol. Biol. Phys.
, vol.33
, pp. 357-364
-
-
Levin, V.A.1
Maor, M.H.2
Thall, P.F.3
Yung, W.K.4
Bruner, J.5
Sawaya, R.6
-
41
-
-
0030067640
-
Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: A phase II study
-
41 Lunardi P., Osman Farah J., Mastronardi L., Puzzilli F. and Lo Bianco F. M. (1996) Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study. Acta Neurochir. Wien 138: 215-220
-
(1996)
Acta Neurochir. Wien
, vol.138
, pp. 215-220
-
-
Lunardi, P.1
Osman Farah, J.2
Mastronardi, L.3
Puzzilli, F.4
Lo Bianco, F.M.5
-
42
-
-
0028618433
-
Superiority of PCNU over AZQ in the treatment of primary brain tumors: Results of a prospective randomized trial (81-20) by the brain tumor study group
-
42 Malkin M. G., Green S. B., Byar D. P., Strike T. A., Burger P. C., Vogel F. S. et al. (1994) Superiority of PCNU over AZQ in the treatment of primary brain tumors: results of a prospective randomized trial (81-20) by the Brain Tumor Study Group. J. Neurooncol. 22: 55-65
-
(1994)
J. Neurooncol.
, vol.22
, pp. 55-65
-
-
Malkin, M.G.1
Green, S.B.2
Byar, D.P.3
Strike, T.A.4
Burger, P.C.5
Vogel, F.S.6
-
43
-
-
0027160503
-
Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas
-
43 Newton H. B., Bromberg J., Junck L., Page M. A. and Greenberg H. S. (1993) Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. J. Neurooncol. 15: 257-263
-
(1993)
J. Neurooncol.
, vol.15
, pp. 257-263
-
-
Newton, H.B.1
Bromberg, J.2
Junck, L.3
Page, M.A.4
Greenberg, H.S.5
-
44
-
-
9444291844
-
Phase II study of paclitaxel in patients with recurrent malignant glioma
-
44 Prados M. D., Schold S. C., Spence A. M., Berger M. S., McAllister L. D., Mehta M. P. et al. (1996) Phase II study of paclitaxel in patients with recurrent malignant glioma. J. Clin. Oncol. 14: 2316-2321
-
(1996)
J. Clin. Oncol.
, vol.14
, pp. 2316-2321
-
-
Prados, M.D.1
Schold, S.C.2
Spence, A.M.3
Berger, M.S.4
McAllister, L.D.5
Mehta, M.P.6
-
45
-
-
0031963150
-
Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors
-
45 Prados M. D., Larson D. A., Lamborn K., McDermott M. W., Sneed P. K., Wara W. M. et al. (1998) Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. Int. J. Radiat. Oncol. Biol. Phys. 40: 57-63
-
(1998)
Int. J. Radiat. Oncol. Biol. Phys.
, vol.40
, pp. 57-63
-
-
Prados, M.D.1
Larson, D.A.2
Lamborn, K.3
McDermott, M.W.4
Sneed, P.K.5
Wara, W.M.6
-
46
-
-
0028129321
-
Multimodality management of recurrent adult malignant gliomas: Results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery
-
46 Rostomily R. C., Spence A. M., Duong D., McCormick K., Bland M. and Berger M. S. (1994) Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 35: 378-388
-
(1994)
Neurosurgery
, vol.35
, pp. 378-388
-
-
Rostomily, R.C.1
Spence, A.M.2
Duong, D.3
McCormick, K.4
Bland, M.5
Berger, M.S.6
-
47
-
-
0030445597
-
Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: A phase II study
-
47 Sanson M., Ameri A., Monjour A., Sahmoud T., Ronchin P., Poisson M. et al. (1996) Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. Eur. J. Cancer 32A: 2229-2235
-
(1996)
Eur. J. Cancer
, vol.32 A
, pp. 2229-2235
-
-
Sanson, M.1
Ameri, A.2
Monjour, A.3
Sahmoud, T.4
Ronchin, P.5
Poisson, M.6
-
48
-
-
0027462531
-
Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma
-
48 Schold S. C. Jr, Herndon J. E., Burger P. C., Halperin E. C., Vick N. A., Cairncross J. G. et al. (1993) Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma. J. Clin. Oncol. 11: 77-83
-
(1993)
J. Clin. Oncol.
, vol.11
, pp. 77-83
-
-
Schold S.C., Jr.1
Herndon, J.E.2
Burger, P.C.3
Halperin, E.C.4
Vick, N.A.5
Cairncross, J.G.6
-
49
-
-
0030791352
-
Clinical trial of external beam-radiotherapy combined with daily administration of low-dose cisplatin for supratentorial glioblastoma multiforme a pilot study
-
49 Shinoda J., Sakai N., Hara A., Ueda T., Sakai H. and Nakatani K. (1997) Clinical trial of external beam-radiotherapy combined with daily administration of low-dose cisplatin for supratentorial glioblastoma multiforme a pilot study. J. Neurooncol. 35: 73-80
-
(1997)
J. Neurooncol.
, vol.35
, pp. 73-80
-
-
Shinoda, J.1
Sakai, N.2
Hara, A.3
Ueda, T.4
Sakai, H.5
Nakatani, K.6
-
50
-
-
0026544396
-
Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure
-
50 Spence A. M., Berger M. S., Livingston R. B., Ali Osman F. and Griffin B. (1992) Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. J. Neurooncol. 12: 187-191
-
(1992)
J. Neurooncol.
, vol.12
, pp. 187-191
-
-
Spence, A.M.1
Berger, M.S.2
Livingston, R.B.3
Ali Osman, F.4
Griffin, B.5
-
51
-
-
0029034516
-
A phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults
-
51 Stewart D. J., Dahrouge S. and Soltys K. (1995) A phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults. J. Neurooncol. 23: 249-252
-
(1995)
J. Neurooncol.
, vol.23
, pp. 249-252
-
-
Stewart, D.J.1
Dahrouge, S.2
Soltys, K.3
-
52
-
-
0031040639
-
Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas
-
52 Stewart D. J., Dahrouge S., Agboola O. and Girard A. (1997) Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas. J. Neurooncol. 32: 161-168
-
(1997)
J. Neurooncol.
, vol.32
, pp. 161-168
-
-
Stewart, D.J.1
Dahrouge, S.2
Agboola, O.3
Girard, A.4
-
53
-
-
0026595777
-
Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas
-
53 Yung W. K., Janus T. J., Maor M. and Feun L. G. (1992) Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas. J. Neurooncol. 12: 131-135
-
(1992)
J. Neurooncol.
, vol.12
, pp. 131-135
-
-
Yung, W.K.1
Janus, T.J.2
Maor, M.3
Feun, L.G.4
-
54
-
-
0028947130
-
Phase II study of amonafide in patients with recurrent glioma
-
54 Levitt R., Buckner J. C., Cascino T. L., Burch P. A., Morton R. F., Westberg M. W. et al. (1995) Phase II study of amonafide in patients with recurrent glioma. J. Neurooncol. 23: 87-93
-
(1995)
J. Neurooncol.
, vol.23
, pp. 87-93
-
-
Levitt, R.1
Buckner, J.C.2
Cascino, T.L.3
Burch, P.A.4
Morton, R.F.5
Westberg, M.W.6
-
55
-
-
0032005473
-
Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: A retrospective comparison of survival data from the northern california oncology group (NCOG) and radiation therapy oncology group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma
-
55 Prados M. D., Scott C. B., Rotman M., Rubin P., Murray K., Sause W. et al. (1998) Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma. Int. J. Radial. Oncol. Biol. Phys. 40: 653-659
-
(1998)
Int. J. Radial. Oncol. Biol. Phys.
, vol.40
, pp. 653-659
-
-
Prados, M.D.1
Scott, C.B.2
Rotman, M.3
Rubin, P.4
Murray, K.5
Sause, W.6
-
56
-
-
0031424068
-
Long-term response to crisnatol mesylate in patients with glioma
-
56 New P., Vokes E., Rogers L., Bazan C., Hohneker J., Eble M. et al. (1997) Long-term response to crisnatol mesylate in patients with glioma. Invest. New Drugs 15: 343-352
-
(1997)
Invest. New Drugs
, vol.15
, pp. 343-352
-
-
New, P.1
Vokes, E.2
Rogers, L.3
Bazan, C.4
Hohneker, J.5
Eble, M.6
-
57
-
-
0028107037
-
Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas
-
57 Hildebrand J., Sahmoud T., Mignolet F., Brucher J. M. and Afra D. (1994) Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology 44: 1479-1483
-
(1994)
Neurology
, vol.44
, pp. 1479-1483
-
-
Hildebrand, J.1
Sahmoud, T.2
Mignolet, F.3
Brucher, J.M.4
Afra, D.5
-
58
-
-
0023221237
-
Phase I-II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors
-
58 Levin V. A., Chamberlain M. C., Prados M. D., Choucair A. K., Berger M. S., Silver P. et al. (1987) Phase I-II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors. Cancer Treat. Rep. 71: 459-464
-
(1987)
Cancer Treat. Rep.
, vol.71
, pp. 459-464
-
-
Levin, V.A.1
Chamberlain, M.C.2
Prados, M.D.3
Choucair, A.K.4
Berger, M.S.5
Silver, P.6
-
59
-
-
0028278131
-
Clinical and biological studies of estramustine phosphate as a novel radiation sensitizer
-
59 Kim J. H., Khil M. S., Kim S. H., Ryu S. and Gabel M. (1994) Clinical and biological studies of estramustine phosphate as a novel radiation sensitizer. Int. J. Radiat. Oncol. Biol. Phys. 29: 555-557
-
(1994)
Int. J. Radiat. Oncol. Biol. Phys.
, vol.29
, pp. 555-557
-
-
Kim, J.H.1
Khil, M.S.2
Kim, S.H.3
Ryu, S.4
Gabel, M.5
-
60
-
-
0025878868
-
Phase II study of fotemustine in recurrent supratentorial malignant gliomas
-
60 Frenay M., Giroux B., Khoury S., Derlon J. M. and Namer M. (1991) Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur. J. Cancer 27: 852-856
-
(1991)
Eur. J. Cancer
, vol.27
, pp. 852-856
-
-
Frenay, M.1
Giroux, B.2
Khoury, S.3
Derlon, J.M.4
Namer, M.5
-
61
-
-
0032910182
-
Gemcitabine cytotoxicity of human malignant glioma cells: Modulation by antioxidants, BCL-2 and dexamethasone
-
61 Rieger J., Durka S., Streffer J., Dichgans J. and Weller M. (1999) Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. Eur. J. Pharmacol. 365: 301-308
-
(1999)
Eur. J. Pharmacol.
, vol.365
, pp. 301-308
-
-
Rieger, J.1
Durka, S.2
Streffer, J.3
Dichgans, J.4
Weller, M.5
-
62
-
-
0026576715
-
Anthracyclines and their C-13 alcohol metabolites: Growth inhibition and DNA damage following incubation with human tumor cells in culture
-
62 Kuffel M. J., Reid J. M. and Ames M. M. (1992) Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother. Pharmacol. 30: 51-57
-
(1992)
Cancer Chemother. Pharmacol.
, vol.30
, pp. 51-57
-
-
Kuffel, M.J.1
Reid, J.M.2
Ames, M.M.3
-
63
-
-
0026766720
-
Phase II study of weekly intravenous menogaril in the treatment of recurrent astrocytomas in adults
-
63 Stewart D. J., Hugenholtz H., DaSilva V. F., Benoit B. G., Richard M. T., Verma S. et al. (1992) Phase II study of weekly intravenous menogaril in the treatment of recurrent astrocytomas in adults. J. Neurooncol. 13: 183-188
-
(1992)
J. Neurooncol.
, vol.13
, pp. 183-188
-
-
Stewart, D.J.1
Hugenholtz, H.2
DaSilva, V.F.3
Benoit, B.G.4
Richard, M.T.5
Verma, S.6
-
64
-
-
0031470996
-
Phase II trial of merbarone in patients with malignant brain tumors
-
64 Malik U. R., Dutcher J. P., Caliendo G., Lasala P., Mitnick R. and Wiernik P. H. (1997) Phase II trial of merbarone in patients with malignant brain tumors. Med. Oncol. 14: 159-162
-
(1997)
Med. Oncol.
, vol.14
, pp. 159-162
-
-
Malik, U.R.1
Dutcher, J.P.2
Caliendo, G.3
Lasala, P.4
Mitnick, R.5
Wiernik, P.H.6
-
65
-
-
0029063579
-
Phase 1 study of phenylacetate administered twice daily to patients with cancer
-
65 Thibault A., Samid D., Cooper M. R., Figg W. D., Tompkins A. C., Patronas N. et al. (1995) Phase 1 study of phenylacetate administered twice daily to patients with cancer. Cancer 75: 2932-2938
-
(1995)
Cancer
, vol.75
, pp. 2932-2938
-
-
Thibault, A.1
Samid, D.2
Cooper, M.R.3
Figg, W.D.4
Tompkins, A.C.5
Patronas, N.6
-
66
-
-
9344238245
-
Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: An open pilot study
-
66 Salazar A. M., Levy H. B., Ondra S., Kende M., Scherokman B., Brown D, et al. (1996) Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery 38: 1096-1103
-
(1996)
Neurosurgery
, vol.38
, pp. 1096-1103
-
-
Salazar, A.M.1
Levy, H.B.2
Ondra, S.3
Kende, M.4
Scherokman, B.5
Brown, D.6
-
67
-
-
0030994384
-
All-trans-retinoic acid: A phase II radiation therapy oncology group study (RTOG 91-13) in patients with recurrent malignant astrocytoma
-
67 Phuphanich S., Scott C., Fischbach A. J., Langer C. and Yung W. K. (1997) All-trans-retinoic acid: a phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma. J. Neurooncol. 34: 193-200
-
(1997)
J. Neurooncol.
, vol.34
, pp. 193-200
-
-
Phuphanich, S.1
Scott, C.2
Fischbach, A.J.3
Langer, C.4
Yung, W.K.5
-
68
-
-
0026672032
-
The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: Preliminary results in a series of "failed" patients
-
68 Vertosick F. T. Jr, Selker R. G., Pollack I. F, and Arena V. (1992) The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of "failed" patients. Neurosurgery 30: 897-902
-
(1992)
Neurosurgery
, vol.30
, pp. 897-902
-
-
Vertosick F.T., Jr.1
Selker, R.G.2
Pollack, I.F.3
Arena, V.4
-
69
-
-
0030002074
-
Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen
-
69 Couldwell W. T., Hinton D. R., Surnock A. A., DeGiorgio C. M., Weiner L. P., Apuzzo M. L. et al. (1996) Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin. Cancer Res. 2: 619-622
-
(1996)
Clin. Cancer Res.
, vol.2
, pp. 619-622
-
-
Couldwell, W.T.1
Hinton, D.R.2
Surnock, A.A.3
DeGiorgio, C.M.4
Weiner, L.P.5
Apuzzo, M.L.6
-
70
-
-
0000414874
-
Randomized trial of temodar® (TEM) versus procarbazine (PCB) in glioblastoma multiforme at first relapse
-
70 Yung A., Levin V., Albright R., Olson J., Fredericks R., Fink K. et al. (1998) Randomized trial of Temodar® (TEM) versus procarbazine (PCB) in glioblastoma multiforme at first relapse. J. Neurooncol. 39: 102
-
(1998)
J. Neurooncol.
, vol.39
, pp. 102
-
-
Yung, A.1
Levin, V.2
Albright, R.3
Olson, J.4
Fredericks, R.5
Fink, K.6
-
71
-
-
0030765194
-
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma
-
71 Bower M., Newlands E. S., Bleehen N. M., Brada M., Begent R. J., Calvert H. et al. (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother. Pharmacol. 40: 484-488
-
(1997)
Cancer Chemother. Pharmacol.
, vol.40
, pp. 484-488
-
-
Bower, M.1
Newlands, E.S.2
Bleehen, N.M.3
Brada, M.4
Begent, R.J.5
Calvert, H.6
-
72
-
-
0029915134
-
Phase II study of topotecan in patients with recurrent malignant glioma
-
72 Macdonald D., Cairncross G., Stewart D., Forsyth P., Sawka C., Wainman N. et al. (1996) Phase II study of topotecan in patients with recurrent malignant glioma. Ann. Oncol. 7: 205-207
-
(1996)
Ann. Oncol.
, vol.7
, pp. 205-207
-
-
Macdonald, D.1
Cairncross, G.2
Stewart, D.3
Forsyth, P.4
Sawka, C.5
Wainman, N.6
-
73
-
-
17744402925
-
Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximinein human malignant glioma cells: The role of bcl-2
-
73 Reber U., Wüllner U., Trepel M., Baumgart J., Seyfried J., Klockgether T. et al. (1998) Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximinein human malignant glioma cells: the role of bcl-2. Biochem. Pharmacol. 55: 349-359
-
(1998)
Biochem. Pharmacol.
, vol.55
, pp. 349-359
-
-
Reber, U.1
Wüllner, U.2
Trepel, M.3
Baumgart, J.4
Seyfried, J.5
Klockgether, T.6
-
74
-
-
0031668233
-
Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors
-
74 Hanley M. L., Elion G. B., Colvin O. M., Modrich P. L., Keir S., Adams D. J. et al. (1998) Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors. Cancer Chemother. Pharmacol. 42: 479-482
-
(1998)
Cancer Chemother. Pharmacol.
, vol.42
, pp. 479-482
-
-
Hanley, M.L.1
Elion, G.B.2
Colvin, O.M.3
Modrich, P.L.4
Keir, S.5
Adams, D.J.6
-
75
-
-
0026591763
-
A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma
-
75 Shapiro W. R., Green S. B., Burger P. C., Selker R. G., VanGilder J. C., Robertson J. T. et al. (1992) A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J. Neurosurg. 76: 772-781
-
(1992)
J. Neurosurg.
, vol.76
, pp. 772-781
-
-
Shapiro, W.R.1
Green, S.B.2
Burger, P.C.3
Selker, R.G.4
VanGilder, J.C.5
Robertson, J.T.6
-
76
-
-
0026510256
-
Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas
-
76 Dropcho E. J., Rosenfeld S. S., Morawetz R. B., Vitek J., Brothers M., Gorum T. et al. (1992) Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. J. Clin. Oncol. 10: 452-458
-
(1992)
J. Clin. Oncol.
, vol.10
, pp. 452-458
-
-
Dropcho, E.J.1
Rosenfeld, S.S.2
Morawetz, R.B.3
Vitek, J.4
Brothers, M.5
Gorum, T.6
-
77
-
-
0028917333
-
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
-
77 Brem H., Piantadosi S., Burger P. C., Walker M., Selker R., Vick N. A. et al. (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345: 1008-1012
-
(1995)
Lancet
, vol.345
, pp. 1008-1012
-
-
Brem, H.1
Piantadosi, S.2
Burger, P.C.3
Walker, M.4
Selker, R.5
Vick, N.A.6
-
78
-
-
0029582768
-
The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase I trial
-
78 Brem H., Ewend M. G., Piantadosi S., Greenhoot J., Burger P. C. and Sisti M. (1995) The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J. Neurooncol. 26: 111-123
-
(1995)
J. Neurooncol.
, vol.26
, pp. 111-123
-
-
Brem, H.1
Ewend, M.G.2
Piantadosi, S.3
Greenhoot, J.4
Burger, P.C.5
Sisti, M.6
-
79
-
-
0026438269
-
Neoadjuvant chemotherapy in the treatment of recurrent glioblastomas (GBM)
-
79 Boiardi A., Silvani A., Croci D., Perego E. and Solero C. L. (1992) Neoadjuvant chemotherapy in the treatment of recurrent glioblastomas (GBM). Ital. J. Neurol. Sci. 13: 583-588
-
(1992)
Ital. J. Neurol. Sci.
, vol.13
, pp. 583-588
-
-
Boiardi, A.1
Silvani, A.2
Croci, D.3
Perego, E.4
Solero, C.L.5
-
80
-
-
0029991845
-
Pre-radiation chemotherapy for malignant glioma in adults
-
80 Kirby S., Macdonald D., Fisher B., Gaspar L. and Cairncross G. (1996) Pre-radiation chemotherapy for malignant glioma in adults. Can. J. Neurol. Sci. 23: 123-127
-
(1996)
Can. J. Neurol. Sci.
, vol.23
, pp. 123-127
-
-
Kirby, S.1
Macdonald, D.2
Fisher, B.3
Gaspar, L.4
Cairncross, G.5
-
81
-
-
0026598909
-
Immunotoxins and central nervous system neoplasia
-
81 Hall W. A. and Fodstad O. (1992) Immunotoxins and central nervous system neoplasia. J. Neurosurg. 76: 1-12
-
(1992)
J. Neurosurg.
, vol.76
, pp. 1-12
-
-
Hall, W.A.1
Fodstad, O.2
-
82
-
-
0028273552
-
Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice
-
82 Laske D. W., Ilercil O., Akbasak A., Youle R. J. and Oldfield E. H. (1994) Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J. Neurosurg. 80: 520-526
-
(1994)
J. Neurosurg.
, vol.80
, pp. 520-526
-
-
Laske, D.W.1
Ilercil, O.2
Akbasak, A.3
Youle, R.J.4
Oldfield, E.H.5
-
83
-
-
7144261725
-
The class III variant of the epidermal growth factor receptor (EGFRvIII): Characterization and utilization as an immunotherapeutic: Target
-
83 Wikstrand C. J., Reist C. J., Archer G. E., Zalutsky M. R. and Bigner D. D. (1998) The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic: target. J. Neurovirol. 4: 148-158
-
(1998)
J. Neurovirol.
, vol.4
, pp. 148-158
-
-
Wikstrand, C.J.1
Reist, C.J.2
Archer, G.E.3
Zalutsky, M.R.4
Bigner, D.D.5
-
84
-
-
0028176650
-
T-cell based cancer immunotherapy: Direct or redirected tumor-cell recognition?
-
84 Beun G. D., Velde C. J. van de and Fleuren G. J. (1994) T-cell based cancer immunotherapy: direct or redirected tumor-cell recognition? Immunol. Today 15: 11-15
-
(1994)
Immunol. Today
, vol.15
, pp. 11-15
-
-
Beun, G.D.1
Van De Velde, C.J.2
Fleuren, G.J.3
-
85
-
-
0025161953
-
Preliminary trial of specific targeting therapy against malignant glioma
-
85 Nitta T., Sato K., Yagita H., Okumura K. and Ishii S. (1990) Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335: 368-371
-
(1990)
Lancet
, vol.335
, pp. 368-371
-
-
Nitta, T.1
Sato, K.2
Yagita, H.3
Okumura, K.4
Ishii, S.5
-
86
-
-
0023918761
-
Immunoregulatory effects of interleukin 2 and interferon on syngeneie murine malignant glioma-specific cytotoxic T-lymphocytes
-
86 Yamasaki T., Kikuchi H., Yamashita J., Handa H., Kuwata S., Taguchi M. et al. (1988) Immunoregulatory effects of interleukin 2 and interferon on syngeneie murine malignant glioma-specific cytotoxic T-lymphocytes. Cancer Res. 48: 2981-2987
-
(1988)
Cancer Res.
, vol.48
, pp. 2981-2987
-
-
Yamasaki, T.1
Kikuchi, H.2
Yamashita, J.3
Handa, H.4
Kuwata, S.5
Taguchi, M.6
-
87
-
-
0030844836
-
Neurotoxic consequences of central long-term administration of interleukin-2 in rats
-
87 Hanisch U. K., Neuhaus J., Rowe W., Van Rossum D., Moller T., Kettenmann H. et al. (1997) Neurotoxic consequences of central long-term administration of interleukin-2 in rats. Neuroscience 79: 799-818
-
(1997)
Neuroscience
, vol.79
, pp. 799-818
-
-
Hanisch, U.K.1
Neuhaus, J.2
Rowe, W.3
Van Rossum, D.4
Moller, T.5
Kettenmann, H.6
-
88
-
-
0029145309
-
Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma
-
88 Hayes R. L., Koslow M., Hiesiger E. M., Hymes K. B., Hochster H. S., Moore E. J. et al. (1995) Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76: 840-852
-
(1995)
Cancer
, vol.76
, pp. 840-852
-
-
Hayes, R.L.1
Koslow, M.2
Hiesiger, E.M.3
Hymes, K.B.4
Hochster, H.S.5
Moore, E.J.6
-
89
-
-
0025745414
-
Modulation of T-cell function by gliomas
-
89 Roszman T., Elliott L. and Brooks W. (1991) Modulation of T-cell function by gliomas. Immunol. Today 12: 370-374
-
(1991)
Immunol. Today
, vol.12
, pp. 370-374
-
-
Roszman, T.1
Elliott, L.2
Brooks, W.3
-
90
-
-
0025000864
-
Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity
-
90 Gansbacher B., Zier K., Daniels B., Cronin K., Bannerji R. and Gilboa E. (1990) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172: 1217-1224
-
(1990)
J. Exp. Med.
, vol.172
, pp. 1217-1224
-
-
Gansbacher, B.1
Zier, K.2
Daniels, B.3
Cronin, K.4
Bannerji, R.5
Gilboa, E.6
-
91
-
-
0028218528
-
In vivo transfer of the human interleukin-2 gene: Negative tumoricidal results in experimental brain tumors
-
91 Ram Z., Walbridge S., Heiss J. D., Culver K. W., Blaese R. M. and Oldfield E. H. (1994) In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. J. Neurosurg. 80: 535-540
-
(1994)
J. Neurosurg.
, vol.80
, pp. 535-540
-
-
Ram, Z.1
Walbridge, S.2
Heiss, J.D.3
Culver, K.W.4
Blaese, R.M.5
Oldfield, E.H.6
-
92
-
-
0028907313
-
Rg-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-γ
-
92 Tjuvajev J., Gansbacher B., Desai R., Beattie B., Kaplitt M., Matci C. et al. (1995) RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-γ. Cancer Res. 55: 1902-1910
-
(1995)
Cancer Res.
, vol.55
, pp. 1902-1910
-
-
Tjuvajev, J.1
Gansbacher, B.2
Desai, R.3
Beattie, B.4
Kaplitt, M.5
Matci, C.6
-
93
-
-
0029865486
-
Eradication of established intracranial rat gliomas by transforming growth factor beta anti-sense gene therapy
-
93 Fakhrai H., Dorigo O., Shawler D. L., Lin H., Mercola D., Black K. L, et al. (1996) Eradication of established intracranial rat gliomas by transforming growth factor beta anti-sense gene therapy. Proc. Natl. Acad. Sci. USA 93: 2909-2914
-
(1996)
Proc. Natl. Acad. Sci. USA
, vol.93
, pp. 2909-2914
-
-
Fakhrai, H.1
Dorigo, O.2
Shawler, D.L.3
Lin, H.4
Mercola, D.5
Black, K.L.6
-
94
-
-
0026581987
-
Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1
-
94 Inge T. H., Hoover S. K., Susskind B. M., Barrett S. K. and Bear H. D. (1992) Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Cancer Res. 52: 1386-1392
-
(1992)
Cancer Res.
, vol.52
, pp. 1386-1392
-
-
Inge, T.H.1
Hoover, S.K.2
Susskind, B.M.3
Barrett, S.K.4
Bear, H.D.5
-
95
-
-
0023689464
-
TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity
-
95 Grimm E. A., Crump W. L. 3rd, Durett A., Hester J. P., Lugoo Deenadalayan S. and Owen Schaub L. B. (1988) TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity. Cancer Immunol. Immunother. 27: 53-58
-
(1988)
Cancer Immunol. Immunother.
, vol.27
, pp. 53-58
-
-
Grimm, E.A.1
Crump W.L. III2
Durett, A.3
Hester, J.P.4
Lugoo Deenadalayan, S.5
Owen Schaub, L.B.6
-
96
-
-
0028217047
-
Nervous tissue as an immune compartment: The dialect of the immune response in the CNS
-
96 Fabry Z., Raine C. S. and Hart M. N. (1994) Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. Immunol. Today 15: 218-224
-
(1994)
Immunol. Today
, vol.15
, pp. 218-224
-
-
Fabry, Z.1
Raine, C.S.A.2
Hart, M.N.3
-
97
-
-
0027320628
-
Inhibition of interferon-γ-induced major histocompatibility complex class II gene transcription by interferon-beta and type beta 1 transforming growth factor in human astrocyloma cells: Definition of cis-element
-
97 Devajyothi C., Kalvakolanu I., Babcock G. T., Vasavada H. A., Howe P. H. and Ransohoff R. M. (1993) Inhibition of interferon-γ-induced major histocompatibility complex class II gene transcription by interferon-beta and type beta 1 transforming growth factor in human astrocyloma cells: definition of cis-element. J. Biol. Chem. 268: 18794-18800
-
(1993)
J. Biol. Chem.
, vol.268
, pp. 18794-18800
-
-
Devajyothi, C.1
Kalvakolanu, I.2
Babcock, G.T.3
Vasavada, H.A.4
Howe, P.H.5
Ransohoff, R.M.6
-
98
-
-
0023760336
-
Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells
-
98 Zuber P., Kuppner M. C. and Tribolet N. de (1988) Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells. Eur. J. Immunol. 18: 1623-1626
-
(1988)
Eur. J. Immunol.
, vol.18
, pp. 1623-1626
-
-
Zuber, P.1
Kuppner, M.C.2
De Tribolet, N.3
-
99
-
-
0026546822
-
Effects of γ-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: Implications for strategies of immunotherapy
-
99 Wen P. Y., Lampson M. A. and Lampson L. A. (1992) Effects of γ-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: implications for strategies of immunotherapy. J. Neuroimmunol. 36: 57-68
-
(1992)
J. Neuroimmunol.
, vol.36
, pp. 57-68
-
-
Wen, P.Y.1
Lampson, M.A.2
Lampson, L.A.3
-
100
-
-
0032506347
-
IFNγ inhibition of cell growth in glioblastomas correlates with increased levels of the eyelin dependent kinase inhibitor p21WAF1/CIP1
-
100 Kominsky S., Johnson H. M., Bryan G., Tanabe T., Hobeika A. C., Subramaniam P. S. et al. (1998) IFNγ inhibition of cell growth in glioblastomas correlates with increased levels of the eyelin dependent kinase inhibitor p21WAF1/CIP1. Oncogene 17: 2973-2979
-
(1998)
Oncogene
, vol.17
, pp. 2973-2979
-
-
Kominsky, S.1
Johnson, H.M.2
Bryan, G.3
Tanabe, T.4
Hobeika, A.C.5
Subramaniam, P.S.6
-
101
-
-
0028275672
-
Randomised, controlled study of intratumoral recombinant γ-interferon treatment in newly diagnosed glioblastoma
-
101 Färkkila M., Jaaskelainen J., Kallio M., Blomstedt G., Raininko R., Virkkunen P. et al. (1994) Randomised, controlled study of intratumoral recombinant γ-interferon treatment in newly diagnosed glioblastoma. Br. J. Cancer 70: 138-141
-
(1994)
Br. J. Cancer
, vol.70
, pp. 138-141
-
-
Färkkila, M.1
Jaaskelainen, J.2
Kallio, M.3
Blomstedt, G.4
Raininko, R.5
Virkkunen, P.6
-
102
-
-
0025741380
-
The effects of local and systemic interferon beta (Fiblaferon) on supratentorial malignant cerebral glioma a phase II study
-
102 Wild K. R. von and Knocke T. H. (1991) The effects of local and systemic interferon beta (Fiblaferon) on supratentorial malignant cerebral glioma a phase II study. Neurosurg. Rev. 14: 203-213
-
(1991)
Neurosurg. Rev.
, vol.14
, pp. 203-213
-
-
Von Wild, K.R.1
Knocke, T.H.2
-
103
-
-
0025945333
-
Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: A phase I/II study
-
103 Yung W. K., Prados M., Levin V. A., Fetell M. R., Bennett J., Mahaley M. S. et al. (1991) Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J. Clin. Oncol. 9: 1945-1949
-
(1991)
J. Clin. Oncol.
, vol.9
, pp. 1945-1949
-
-
Yung, W.K.1
Prados, M.2
Levin, V.A.3
Fetell, M.R.4
Bennett, J.5
Mahaley, M.S.6
-
105
-
-
0028177049
-
Tumour necrosis factor-α induces an increase in susceptibility of human glioblastoma U87-MG cells to natural killer cell-mediated lysis
-
105 Kondo S., Yin D., Takeuchi J., Morimura T., Miyatake S. I., Nakatsu S. et al. (1994) Tumour necrosis factor-α induces an increase in susceptibility of human glioblastoma U87-MG cells to natural killer cell-mediated lysis. Br. J. Cancer 69: 627-632
-
(1994)
Br. J. Cancer
, vol.69
, pp. 627-632
-
-
Kondo, S.1
Yin, D.2
Takeuchi, J.3
Morimura, T.4
Miyatake, S.I.5
Nakatsu, S.6
-
106
-
-
0028206935
-
Liposomal transfection of human γ-interferon gene into human glioma cells and adoptive immunotherapy using lymphokine-activated killer cells
-
106 Mizuno M., Yoshida J., Takaoka T. and Sugita K. (1994) Liposomal transfection of human γ-interferon gene into human glioma cells and adoptive immunotherapy using lymphokine-activated killer cells. J. Neurosurg. 80: 510-514
-
(1994)
J. Neurosurg.
, vol.80
, pp. 510-514
-
-
Mizuno, M.1
Yoshida, J.2
Takaoka, T.3
Sugita, K.4
-
107
-
-
0024320829
-
Intratumoural injection of autologous lymphocytes plus human lymphoblastoid interferon for the treatment of glioblasltoma
-
107 Vaquero J., Martinez R., Oya S., Coca S., Barbolla L., Ramiro J. et al. (1989) Intratumoural injection of autologous lymphocytes plus human lymphoblastoid interferon for the treatment of glioblasltoma. Acta Neurochir. Wien 98: 35-41
-
(1989)
Acta Neurochir. Wien
, vol.98
, pp. 35-41
-
-
Vaquero, J.1
Martinez, R.2
Oya, S.3
Coca, S.4
Barbolla, L.5
Ramiro, J.6
-
108
-
-
0027990763
-
Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells:Induction and modulation of sensitivity by cytokines
-
108 Weller M., Frei K., Groscurth P., Krammer P. H., Yonekawa Y. and Fontana A. (1994) Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells:induction and modulation of sensitivity by cytokines. J. Clin. Invest. 94: 954-964
-
(1994)
J. Clin. Invest.
, vol.94
, pp. 954-964
-
-
Weller, M.1
Frei, K.2
Groscurth, P.3
Krammer, P.H.4
Yonekawa, Y.5
Fontana, A.6
-
109
-
-
0032127022
-
Interferon-α enhances CD95L-induced apoptosis of human malignant glioma cells
-
109 Roth W., Wagenknecht B., Dichgans J. and Weller M. (1998) Interferon-α enhances CD95L-induced apoptosis of human malignant glioma cells. J. Neuroimmunol. 87: 121-129
-
(1998)
J. Neuroimmunol.
, vol.87
, pp. 121-129
-
-
Roth, W.1
Wagenknecht, B.2
Dichgans, J.3
Weller, M.4
-
110
-
-
0031973358
-
Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: Association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest
-
110 Roth W., Wagenknecht B., Grimmel C., Dichgans J. and Weller M. (1998) Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest. Br. J. Cancer 77: 404-411
-
(1998)
Br. J. Cancer
, vol.77
, pp. 404-411
-
-
Roth, W.1
Wagenknecht, B.2
Grimmel, C.3
Dichgans, J.4
Weller, M.5
-
111
-
-
0027518307
-
Differential effects of tumor necrosis factor-α on proliferation, cell surface antigen expression, and cytokine interactions in malignant gliomas
-
111 Chen T. C., Hinton D. R., Apuzzo M. L. and Hofman F. M. (1993) Differential effects of tumor necrosis factor-α on proliferation, cell surface antigen expression, and cytokine interactions in malignant gliomas. Neurosurgery 32: 85-94
-
(1993)
Neurosurgery
, vol.32
, pp. 85-94
-
-
Chen, T.C.1
Hinton, D.R.2
Apuzzo, M.L.3
Hofman, F.M.4
-
112
-
-
0026665652
-
Clinical effect of intra-arterial tumor necrosis factor-α for malignant glioma
-
112 Yoshida J., Wakabayashi T., Mizuno M., Sugita K., Yoshida T., Hori S. et al. (1992) Clinical effect of intra-arterial tumor necrosis factor-α for malignant glioma. J. Neurosurg. 77: 78-83
-
(1992)
J. Neurosurg.
, vol.77
, pp. 78-83
-
-
Yoshida, J.1
Wakabayashi, T.2
Mizuno, M.3
Sugita, K.4
Yoshida, T.5
Hori, S.6
-
113
-
-
0027439474
-
Reinforced cytotoxicity of lymphokine-activated killer cells toward glioma cells by transfection with the tumor necrosis factor-α gene
-
113 Tashiro T., Yoshida J., Mizuno M. and Sugita K. (1993) Reinforced cytotoxicity of lymphokine-activated killer cells toward glioma cells by transfection with the tumor necrosis factor-α gene. J. Neurosurg. 78: 252-256
-
(1993)
J. Neurosurg.
, vol.78
, pp. 252-256
-
-
Tashiro, T.1
Yoshida, J.2
Mizuno, M.3
Sugita, K.4
-
114
-
-
0027296846
-
Modulation of proliferation and antigen expression of a cloned human glioblastoma by interleukin-4 alone and in combination with tumor necrosis factor-α and/or interferon-γ
-
114 Iwasaki K., Rogers L. R., Estes M. L. and Barna B. P. (1993) Modulation of proliferation and antigen expression of a cloned human glioblastoma by interleukin-4 alone and in combination with tumor necrosis factor-α and/or interferon-γ. Neurosurgery 33: 489-493
-
(1993)
Neurosurgery
, vol.33
, pp. 489-493
-
-
Iwasaki, K.1
Rogers, L.R.2
Estes, M.L.3
Barna, B.P.4
-
115
-
-
0026657391
-
An cosinophil-dependent mechanism for the antitumor effect of interleukin-4
-
115 Tepper R. I., Coffman R. L. and Leder P. (1992) An cosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257: 548-551
-
(1992)
Science
, vol.257
, pp. 548-551
-
-
Tepper, R.I.1
Coffman, R.L.2
Leder, P.3
-
116
-
-
0027203715
-
Treatment of glioma by engineered interleukin 4-secreting cells
-
116 Yu J. S., Wei M. X., Chiocca E. A., Martuza R. L. and Tepper R. I. (1993) Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res. 53: 3125-3128
-
(1993)
Cancer Res.
, vol.53
, pp. 3125-3128
-
-
Yu, J.S.1
Wei, M.X.2
Chiocca, E.A.3
Martuza, R.L.4
Tepper, R.I.5
-
117
-
-
0026645274
-
Sensitivity of human glioma and brain cells to natural killer cell lysis. Effects of serum concentration, epidermal growth factor, and time in culture
-
117 Myers R. L., Whisler R. L., Stephens R. E., Sponseller C. A., Livingston K., Spring P. M. et al. (1992) Sensitivity of human glioma and brain cells to natural killer cell lysis. Effects of serum concentration, epidermal growth factor, and time in culture. J. Neurosurg. 76: 986-990
-
(1992)
J. Neurosurg.
, vol.76
, pp. 986-990
-
-
Myers, R.L.1
Whisler, R.L.2
Stephens, R.E.3
Sponseller, C.A.4
Livingston, K.5
Spring, P.M.6
-
118
-
-
0027230753
-
Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma
-
118 Kruse C. A., Mitchell D. H., Kleinschmidt DeMasters B. K., Bellgrau D., Eule J. M., Parra J. R. et al. (1993) Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma. J. Neurooncol. 15: 97-112
-
(1993)
J. Neurooncol.
, vol.15
, pp. 97-112
-
-
Kruse, C.A.1
Mitchell, D.H.2
Kleinschmidt DeMasters, B.K.3
Bellgrau, D.4
Eule, J.M.5
Parra, J.R.6
-
119
-
-
0024510754
-
Intratumoral LAK cell and interleukin-2 therapy of human gliomas
-
119 Barba D., Saris S. C., Holder C., Rosenberg S. A. and Oldfield E. H. (1989) Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J. Neurosurg. 70: 175-182
-
(1989)
J. Neurosurg.
, vol.70
, pp. 175-182
-
-
Barba, D.1
Saris, S.C.2
Holder, C.3
Rosenberg, S.A.4
Oldfield, E.H.5
-
120
-
-
0028108663
-
Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients
-
120 Boiardi A., Silvani A., Ruffini P. A., Rivoltini L., Parmiani G., Broggi G. et al. (1994) Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol. Immunother. 39: 193-197
-
(1994)
Cancer Immunol. Immunother.
, vol.39
, pp. 193-197
-
-
Boiardi, A.1
Silvani, A.2
Ruffini, P.A.3
Rivoltini, L.4
Parmiani, G.5
Broggi, G.6
-
121
-
-
0022641036
-
Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: Phase I trial
-
121 Jacobs S. K., Wilson D. J., Kornblith P. L. and Grimm E. A. (1986) Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res. 46: 2101-2104
-
(1986)
Cancer Res.
, vol.46
, pp. 2101-2104
-
-
Jacobs, S.K.1
Wilson, D.J.2
Kornblith, P.L.3
Grimm, E.A.4
-
122
-
-
0027314032
-
Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes. I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA
-
122 Jeffes E. W. 3rd, Beamer Y. B., Jacques S., Silberman R. S., Vayuvegula B., Gupta S. et al. (1993) Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes. I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA. J. Neurooncol. 15: 141-155
-
(1993)
J. Neurooncol.
, vol.15
, pp. 141-155
-
-
Jeffes E.W. III1
Beamer, Y.B.2
Jacques, S.3
Silberman, R.S.4
Vayuvegula, B.5
Gupta, S.6
-
123
-
-
0025974603
-
Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy
-
123 Lillehei K. O., Mitchell D. H., Johnson S. D., McCleary E. L. and Kruse C. A. (1991) Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 28: 16-23
-
(1991)
Neurosurgery
, vol.28
, pp. 16-23
-
-
Lillehei, K.O.1
Mitchell, D.H.2
Johnson, S.D.3
McCleary, E.L.4
Kruse, C.A.5
-
124
-
-
0024210594
-
Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor
-
124 Merchant R. E., Merchant L. H., Cook S. H., McVicar D. W. and Young H. F. (1988) Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery 23: 725-732
-
(1988)
Neurosurgery
, vol.23
, pp. 725-732
-
-
Merchant, R.E.1
Merchant, L.H.2
Cook, S.H.3
McVicar, D.W.4
Young, H.F.5
-
125
-
-
0030065695
-
Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors
-
125 Sankhla S. K., Nadkarni J. S. and Bhagwati S. N. (1996) Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J. Neurooncol. 27: 133-140
-
(1996)
J. Neurooncol.
, vol.27
, pp. 133-140
-
-
Sankhla, S.K.1
Nadkarni, J.S.2
Bhagwati, S.N.3
-
126
-
-
0028885277
-
Effect of lymphokine-activated killer cells with or without radiation therapy against malignant brain tumors
-
126 Nakagawa K., Kamezaki T., Shibata Y., Tsunoda T., Meguro K. and Nose T. (1995) Effect of lymphokine-activated killer cells with or without radiation therapy against malignant brain tumors. Neurol. Med. Chir. Tokyo. 35: 22-27
-
(1995)
Neurol. Med. Chir. Tokyo.
, vol.35
, pp. 22-27
-
-
Nakagawa, K.1
Kamezaki, T.2
Shibata, Y.3
Tsunoda, T.4
Meguro, K.5
Nose, T.6
-
127
-
-
0026521970
-
Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes
-
127 Saris S. C., Spiess P., Lieberman D. M., Lin S., Walbridge S. and Oldfield E. H. (1992) Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J. Neurosurg. 76: 513-519
-
(1992)
J. Neurosurg.
, vol.76
, pp. 513-519
-
-
Saris, S.C.1
Spiess, P.2
Lieberman, D.M.3
Lin, S.4
Walbridge, S.5
Oldfield, E.H.6
-
128
-
-
0027155436
-
Cancer vaccines
-
128 Pardoll D. M. (1993) Cancer vaccines. Immunol. Today 14: 310-316
-
(1993)
Immunol. Today
, vol.14
, pp. 310-316
-
-
Pardoll, D.M.1
-
129
-
-
0028318967
-
The effect of irradiation on expression of HLA class I antigens in human brain tumors in culture
-
129 Klein B., Loven D., Lurie H., Rakowsky E., Nyska A., Levin I. et al. (1994) The effect of irradiation on expression of HLA class I antigens in human brain tumors in culture. J. Neurosurg. 80: 1074-1077
-
(1994)
J. Neurosurg.
, vol.80
, pp. 1074-1077
-
-
Klein, B.1
Loven, D.2
Lurie, H.3
Rakowsky, E.4
Nyska, A.5
Levin, I.6
-
130
-
-
0025984468
-
Expression of MHC class II antigens on human glioma cells modulated by transfection with genes encoding these antigens
-
130 Yoshida S., Takahashi H. and Tanaka R. (1991) Expression of MHC class II antigens on human glioma cells modulated by transfection with genes encoding these antigens. Neurol. Med. Chir. Tokyo. 31: 623-628
-
(1991)
Neurol. Med. Chir. Tokyo.
, vol.31
, pp. 623-628
-
-
Yoshida, S.1
Takahashi, H.2
Tanaka, R.3
-
131
-
-
0027394642
-
Vaccinations with tumor cells genetically engineered to produce different cytokines: Effectivity not superior to a classical adjuvant
-
131 Hock H., Dorsch M., Kunzendorf U., Uberla K., Qin Z., Diamantstein T. et al. (1993) Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res. 53: 714-716
-
(1993)
Cancer Res.
, vol.53
, pp. 714-716
-
-
Hock, H.1
Dorsch, M.2
Kunzendorf, U.3
Uberla, K.4
Qin, Z.5
Diamantstein, T.6
-
132
-
-
0030854533
-
Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells
-
132 Yu J. S., Burwick J. A., Dranoff G. and Breakefield X. O. (1997) Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum. Gene Ther. 8: 1065-1072
-
(1997)
Hum. Gene Ther.
, vol.8
, pp. 1065-1072
-
-
Yu, J.S.1
Burwick, J.A.2
Dranoff, G.3
Breakefield, X.O.4
-
133
-
-
0028967430
-
Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy?
-
133 Grabbe S., Beissert S., Schwarz, T. and Granstein R. D. (1995) Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol. Today 16: 117-121
-
(1995)
Immunol. Today
, vol.16
, pp. 117-121
-
-
Grabbe, S.1
Beissert, S.2
Schwarz, T.3
Granstein, R.D.4
-
134
-
-
0031832638
-
Systemic T cell adoptive immunotherapy of malignant gliomas
-
134 Plautz G. E., Barnett G. H., Miller D. W., Cohen B. H., Prayson R. A., Krauss J. C. et al. (1998) Systemic T cell adoptive immunotherapy of malignant gliomas. J. Neurosurg. 89: 42-51
-
(1998)
J. Neurosurg.
, vol.89
, pp. 42-51
-
-
Plautz, G.E.1
Barnett, G.H.2
Miller, D.W.3
Cohen, B.H.4
Prayson, R.A.5
Krauss, J.C.6
-
135
-
-
0030034580
-
Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/ IV astrocytoma
-
135 Holladay F. P., Heitz Turner T., Bayer W. L. and Wood G. W. (1996) Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/ IV astrocytoma. J. Neurooncol. 27: 179-189
-
(1996)
J. Neurooncol.
, vol.27
, pp. 179-189
-
-
Holladay, F.P.1
Heitz Turner, T.2
Bayer, W.L.3
Wood, G.W.4
-
136
-
-
0028813149
-
Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen
-
136 Treisman J., Hwu P., Minamoto S., Shafer G. E., Cowherd R., Morgan R. A. et al. (1995) Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood 85: 139-145
-
(1995)
Blood
, vol.85
, pp. 139-145
-
-
Treisman, J.1
Hwu, P.2
Minamoto, S.3
Shafer, G.E.4
Cowherd, R.5
Morgan, R.A.6
-
137
-
-
0032893390
-
TGF-β and p21: Multiple molecular targets of decorin-mediated suppression of neoplastic growth
-
137 Ständer M., Naumann U., Wick W. and Weller M. (1999) TGF-β and p21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res. 296: 221-227
-
(1999)
Cell Tissue Res.
, vol.296
, pp. 221-227
-
-
Ständer, M.1
Naumann, U.2
Wick, W.3
Weller, M.4
-
138
-
-
0024390026
-
Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo
-
138 Krosnick J. A., Mulé J. J., McIntosh J. K. and Rosenberg S. A. (1989) Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Cancer Res. 49: 3729-3733
-
(1989)
Cancer Res.
, vol.49
, pp. 3729-3733
-
-
Krosnick, J.A.1
Mulé, J.J.2
McIntosh, J.K.3
Rosenberg, S.A.4
-
139
-
-
0028970787
-
Interferon-alpha or beta potentiate platinum analogous in human glioblastoma cell lines
-
139 Stanzione S., Cimoli G., Debernardis D., Michelotti A., Conte P., Parodi S. et al. (1995) Interferon-alpha or beta potentiate platinum analogous in human glioblastoma cell lines. Mutat. Res. 348: 131-135
-
(1995)
Mutat. Res.
, vol.348
, pp. 131-135
-
-
Stanzione, S.1
Cimoli, G.2
Debernardis, D.3
Michelotti, A.4
Conte, P.5
Parodi, S.6
-
140
-
-
0030896574
-
Immunochemotherapy of malignant glioma: Synergistic activity of CD95 ligand and chemotherapeutics
-
140 Roth W., Fontana A., Trepel M., Reed J. C., Dichgans J. and Weller M. (1997) Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol. Immunother. 44: 55-63
-
(1997)
Cancer Immunol. Immunother.
, vol.44
, pp. 55-63
-
-
Roth, W.1
Fontana, A.2
Trepel, M.3
Reed, J.C.4
Dichgans, J.5
Weller, M.6
-
141
-
-
0030966954
-
Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity
-
141 Micheau O., Solary E., Hammann A., Martin F. and Dimanche Boitrel M. T. (1997) Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J. Natl. Cancer Inst. 89: 783-789
-
(1997)
J. Natl. Cancer Inst.
, vol.89
, pp. 783-789
-
-
Micheau, O.1
Solary, E.2
Hammann, A.3
Martin, F.4
Dimanche Boitrel, M.T.5
-
142
-
-
0033083990
-
Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
-
142 Keane M. M., Ettenberg S. A., Nau M. M., Russell E. K. and Lipkowitz S. (1999) Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 59: 734-741
-
(1999)
Cancer Res.
, vol.59
, pp. 734-741
-
-
Keane, M.M.1
Ettenberg, S.A.2
Nau, M.M.3
Russell, E.K.4
Lipkowitz, S.5
-
143
-
-
0029820016
-
Activation of the CPP32protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents
-
143 Datta R., Banach D., Kojima H., Talanian R. V., Alnemri E. S., Wong W. W. et al. (1996) Activation of the CPP32protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood 88: 1936-1943
-
(1996)
Blood
, vol.88
, pp. 1936-1943
-
-
Datta, R.1
Banach, D.2
Kojima, H.3
Talanian, R.V.4
Alnemri, E.S.5
Wong, W.W.6
-
144
-
-
0029007855
-
The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation
-
144 Hsu H., Xiong J. and Goeddel D. V. (1995) The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 81: 495-504
-
(1995)
Cell
, vol.81
, pp. 495-504
-
-
Hsu, H.1
Xiong, J.2
Goeddel, D.V.3
-
145
-
-
0032567912
-
Cellular responses to interferons and other cytokines: The JAK-STAT paradigm
-
145 Ransohoff R. M. (1998) Cellular responses to interferons and other cytokines: the JAK-STAT paradigm. N. Engl. J. Med. 338: 616-618
-
(1998)
N. Engl. J. Med.
, vol.338
, pp. 616-618
-
-
Ransohoff, R.M.1
-
146
-
-
0025759004
-
Local immunotherapy (beta-IFN) and systemic chemotherapy in primary glial tumors
-
146 Boiardi A., Silvani A., Milanesi I., Munari L., Broggi G. and Botturi M. (1991) Local immunotherapy (beta-IFN) and systemic chemotherapy in primary glial tumors. Ital. J. Neurol. Sci. 12: 163-168
-
(1991)
Ital. J. Neurol. Sci.
, vol.12
, pp. 163-168
-
-
Boiardi, A.1
Silvani, A.2
Milanesi, I.3
Munari, L.4
Broggi, G.5
Botturi, M.6
-
147
-
-
0030856633
-
Phase II trial with BCNU plus α-interferon in patients with recurrent high-grade gliomas
-
147 Brandes A. A., Scelzi E., Zampieri P., Rigon A., Rotilio A., Amista P. et al. (1997) Phase II trial with BCNU plus α-interferon in patients with recurrent high-grade gliomas. Am. J. Clin. Oncol. 20: 364-367
-
(1997)
Am. J. Clin. Oncol.
, vol.20
, pp. 364-367
-
-
Brandes, A.A.1
Scelzi, E.2
Zampieri, P.3
Rigon, A.4
Rotilio, A.5
Amista, P.6
-
148
-
-
0028929258
-
Phase II evaluation of recombinant interferon α and BCNu in recurrent glioma
-
148 Buckner J. C., Brown L. D., Kugler J. W., Cascino T. L., Krook J. E., Mailliard J. A. et al. (1995) Phase II evaluation of recombinant Interferon α and BCNU in recurrent glioma. J. Neurosurg. 82: 430-435
-
(1995)
J. Neurosurg.
, vol.82
, pp. 430-435
-
-
Buckner, J.C.1
Brown, L.D.2
Kugler, J.W.3
Cascino, T.L.4
Krook, J.E.5
Mailliard, J.A.6
-
149
-
-
0031776472
-
Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma
-
149 Buckner J. C., Burch P. A., Cascino T. L., O'Fallon J. R. and Scheithauer B. W. (1998) Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma. J. Neurooncol. 36: 65-70
-
(1998)
J. Neurooncol.
, vol.36
, pp. 65-70
-
-
Buckner, J.C.1
Burch, P.A.2
Cascino, T.L.3
O'Fallon, J.R.A.4
Scheithauer, B.W.5
-
150
-
-
0031950726
-
High dose oral tamoxifen and subcutaneous interferon α-2a for recurrent glioma
-
150 Chang S. M., Barker F. G., Huhn S. L., Nicholas M. K., Page M., Rabbitt J. et al. (1998) High dose oral tamoxifen and subcutaneous interferon α-2a for recurrent glioma. J. Neurooncol. 37: 169-176
-
(1998)
J. Neurooncol.
, vol.37
, pp. 169-176
-
-
Chang, S.M.1
Barker, F.G.2
Huhn, S.L.3
Nicholas, M.K.4
Page, M.5
Rabbitt, J.6
-
151
-
-
0024531767
-
Intratumor application of human leukocyte interferon-α in patients with malignant brain tumors
-
151 Jereb B., Petric J., Lamovec J., Skrbec M. and Soss E. (1989) Intratumor application of human leukocyte interferon-α in patients with malignant brain tumors. Am. J. Clin. Oncol. 12: 1-7
-
(1989)
Am. J. Clin. Oncol.
, vol.12
, pp. 1-7
-
-
Jereb, B.1
Petric, J.2
Lamovec, J.3
Skrbec, M.4
Soss, E.5
-
152
-
-
0028171990
-
Addition of IFN-α to treatment of malignant brain tumors
-
152 Jereb B., Petric Grabnar G., Klun B., Lamovec J., Skrbec M. and Soos E. (1994) Addition of IFN-α to treatment of malignant brain tumors. Acta Oncol. 33: 651-654
-
(1994)
Acta Oncol.
, vol.33
, pp. 651-654
-
-
Jereb, B.1
Petric Grabnar, G.2
Klun, B.3
Lamovec, J.4
Skrbec, M.5
Soos, E.6
-
153
-
-
0029014123
-
Attempted dose intensified cyclophosphamide, etoposide, and granulocyte colony-stimulating factor for treatment of malignant astrocytoma
-
153 Newton H. B. and Newton C. L. (1995) Attempted dose intensified cyclophosphamide, etoposide, and granulocyte colony-stimulating factor for treatment of malignant astrocytoma. J. Neurooncol. 24: 285-292
-
(1995)
J. Neurooncol.
, vol.24
, pp. 285-292
-
-
Newton, H.B.1
Newton, C.L.2
-
154
-
-
0032518351
-
Phase I evaluation of radiation combined with recombinant interferon α-2a and BCNU for patients with high-grade glioma
-
154 Rajkumar S. V., Buckner J. C., Schomberg P. J., Cascino T. L., Burch P. A. and Dinapoli R. P. (1998) Phase I evaluation of radiation combined with recombinant interferon α-2a and BCNU for patients with high-grade glioma. Int. J. Radiat. Oncol. Biol. Phys. 40: 297-302
-
(1998)
Int. J. Radiat. Oncol. Biol. Phys.
, vol.40
, pp. 297-302
-
-
Rajkumar, S.V.1
Buckner, J.C.2
Schomberg, P.J.3
Cascino, T.L.4
Burch, P.A.5
Dinapoli, R.P.6
-
155
-
-
0025542982
-
Intratumoral beta interferon and systemic chemotherapy: Preliminary data in GBM patients
-
155 Silvani A., Milanesi I., Munari L., Broggi G., Botturi M. and Boiardi A. (1990) Intratumoral beta interferon and systemic chemotherapy: preliminary data in GBM patients. J. Neurosurg. Sci. 34: 257-259
-
(1990)
J. Neurosurg. Sci.
, vol.34
, pp. 257-259
-
-
Silvani, A.1
Milanesi, I.2
Munari, L.3
Broggi, G.4
Botturi, M.5
Boiardi, A.6
-
156
-
-
0028345187
-
Long-term follow-up results of 175 patients with malignant glioma: Importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation
-
156 Yoshida J., Kajita Y., Wakabayashi T. and Sugita K. (1994) Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir. Wien 127: 55-59
-
(1994)
Acta Neurochir. Wien
, vol.127
, pp. 55-59
-
-
Yoshida, J.1
Kajita, Y.2
Wakabayashi, T.3
Sugita, K.4
-
157
-
-
0019761119
-
How heterogeneous are gliomas?
-
157 Bigner D. D., Schold C., Bigner S. H., Bullard D. E. and Wikstrand C. (1981) How heterogeneous are gliomas? Cancer Treat. Rep. 65 (Suppl 2): 45-49
-
(1981)
Cancer Treat. Rep.
, vol.65
, Issue.SUPPL. 2
, pp. 45-49
-
-
Bigner, D.D.1
Schold, C.2
Bigner, S.H.3
Bullard, D.E.4
Wikstrand, C.5
-
158
-
-
0020546765
-
Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies
-
158 Wikstrand C. J., Bigner S. H. and Bigner D. D. (1983) Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies. Cancer Res. 43: 3327-3334
-
(1983)
Cancer Res.
, vol.43
, pp. 3327-3334
-
-
Wikstrand, C.J.1
Bigner, S.H.2
Bigner, D.D.3
-
159
-
-
0030271479
-
Unlocking the blood-brain barrier: A role for RMP-7 in brain tumor therapy
-
159 Elliott P. J., Hayward N. J., Huff M. R., Nagle T. L., Black K. L. and Bartus R. T. (1996) Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp. Neurol. 141: 214-224
-
(1996)
Exp. Neurol.
, vol.141
, pp. 214-224
-
-
Elliott, P.J.1
Hayward, N.J.2
Huff, M.R.3
Nagle, T.L.4
Black, K.L.5
Bartus, R.T.6
-
160
-
-
0030888267
-
Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas
-
160 Black K. L., Cloughesy T., Huang S. C., Gobin Y. P., Zhou Y., Grous J. et al. (1997) Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J. Neurosurg. 86: 603-609
-
(1997)
J. Neurosurg.
, vol.86
, pp. 603-609
-
-
Black, K.L.1
Cloughesy, T.2
Huang, S.C.3
Gobin, Y.P.4
Zhou, Y.5
Grous, J.6
-
161
-
-
0032189111
-
A phase 1 study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma
-
161 Ford J., Osborn C., Barton T. and Blechen N. M. (1998) A phase 1 study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Eur. J. Cancer 34: 1807-1811
-
(1998)
Eur. J. Cancer
, vol.34
, pp. 1807-1811
-
-
Ford, J.1
Osborn, C.2
Barton, T.3
Blechen, N.M.4
-
162
-
-
43949160470
-
Inflammatory cytokines in the brain: Does the CNS shape immune responses?
-
162 Owens T., Renno T., Taupin V. and Krakowski M. (1994) Inflammatory cytokines in the brain: does the CNS shape immune responses? Immunol. Today 15: 566-571
-
(1994)
Immunol. Today
, vol.15
, pp. 566-571
-
-
Owens, T.1
Renno, T.2
Taupin, V.3
Krakowski, M.4
-
163
-
-
0026582225
-
Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo
-
163 Aoki T., Tashiro K., Miyatake S., Kinashi T., Nakano T., Oda Y. et al. (1992) Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc. Natl. Acad. Sci. USA 89: 3850-3854
-
(1992)
Proc. Natl. Acad. Sci. USA
, vol.89
, pp. 3850-3854
-
-
Aoki, T.1
Tashiro, K.2
Miyatake, S.3
Kinashi, T.4
Nakano, T.5
Oda, Y.6
-
164
-
-
0027507179
-
Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA
-
164 Trojan J., Johnson T. R., Rudin S. D., Ilan J. and Tykocinski M. L. (1993) Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259: 94-97
-
(1993)
Science
, vol.259
, pp. 94-97
-
-
Trojan, J.1
Johnson, T.R.2
Rudin, S.D.3
Ilan, J.4
Tykocinski, M.L.5
-
165
-
-
0028271497
-
Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors
-
165 Resnicoff M., Sell C., Rubini M., Coppola D., Ambrose D., Baserga R. et al. (1994) Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res. 54: 2218-2222
-
(1994)
Cancer Res.
, vol.54
, pp. 2218-2222
-
-
Resnicoff, M.1
Sell, C.2
Rubini, M.3
Coppola, D.4
Ambrose, D.5
Baserga, R.6
-
166
-
-
0027979670
-
Generation of cytotoxic immune responses during the progression of a rat glioma
-
166 Holladay F. P., Choudhuri R., Heitz T. and Wood G. W. (1994) Generation of cytotoxic immune responses during the progression of a rat glioma. J. Neurosurg. 80: 90-96
-
(1994)
J. Neurosurg.
, vol.80
, pp. 90-96
-
-
Holladay, F.P.1
Choudhuri, R.2
Heitz, T.3
Wood, G.W.4
-
167
-
-
0023239736
-
Immunohistological study of mononuclear cell infiltrate in malignant gliomas
-
167 Rossi M. L., Hughes J. T., Esiri M. M., Coakham H. B. and Brownell D. B. (1987) Immunohistological study of mononuclear cell infiltrate in malignant gliomas. Acta Neuropathol. Berl. 74: 269-277
-
(1987)
Acta Neuropathol. Berl.
, vol.74
, pp. 269-277
-
-
Rossi, M.L.1
Hughes, J.T.2
Esiri, M.M.3
Coakham, H.B.4
Brownell, D.B.5
-
168
-
-
0024212342
-
Immunohistological and functional analyses of lymphoid infiltrates in human glioblastomas
-
168 Kuppner M. C., Hamou M. F. and Tribolet N. de (1988) Immunohistological and functional analyses of lymphoid infiltrates in human glioblastomas. Cancer Res. 48: 6926-6932
-
(1988)
Cancer Res.
, vol.48
, pp. 6926-6932
-
-
Kuppner, M.C.1
Hamou, M.F.2
De Tribolet, N.3
-
169
-
-
0023841573
-
In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers
-
169 Miescher S., Whiteside T. L., Tribolet N. de and Fliedner V. von (1988) In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J. Neurosurg. 68: 438-448
-
(1988)
J. Neurosurg.
, vol.68
, pp. 438-448
-
-
Miescher, S.1
Whiteside, T.L.2
De Tribolet, N.3
Von Fliedner, V.4
-
170
-
-
0029610610
-
The failure of current immunotherapy for malignant glioma: Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain
-
170 Weller M. and Fontana A. (1995) The failure of current immunotherapy for malignant glioma: tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res. Rev. 21: 128-151
-
(1995)
Brain Res. Rev.
, vol.21
, pp. 128-151
-
-
Weller, M.1
Fontana, A.2
-
171
-
-
0026667037
-
Inflammatory leukocytes associated with increased immuno-suppression by glioblastoma
-
171 Black K. L., Chen K., Becker D. P. and Merrill J. E. (1992) Inflammatory leukocytes associated with increased immuno-suppression by glioblastoma. J. Neurosurg. 77: 120-126
-
(1992)
J. Neurosurg.
, vol.77
, pp. 120-126
-
-
Black, K.L.1
Chen, K.2
Becker, D.P.3
Merrill, J.E.4
-
172
-
-
0026093652
-
Modulation of human leukocyte antigenDR expression in glioblastoma cells by interferon γ and other cytokines
-
172 Hong L. L., Johannsen L. and Krueger J. M. (1991) Modulation of human leukocyte antigenDR expression in glioblastoma cells by interferon γ and other cytokines. J. Neuroimmunol. 35: 139-152
-
(1991)
J. Neuroimmunol.
, vol.35
, pp. 139-152
-
-
Hong, L.L.1
Johannsen, L.2
Krueger, J.M.3
-
173
-
-
0028178471
-
Transforming growth factor-beta 2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression
-
173 Weller M., Constam D. B., Malipiero U. and Fontana A. (1994) Transforming growth factor-beta 2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. Eur. J. Immunol. 24: 1293-1300
-
(1994)
Eur. J. Immunol.
, vol.24
, pp. 1293-1300
-
-
Weller, M.1
Constam, D.B.2
Malipiero, U.3
Fontana, A.4
-
174
-
-
0028980745
-
TGF-beta 1 and cyclic AMP promote apoptosis in resting human B lymphocytes
-
174 Lomo J., Blomhoff H. K., Beiske K., Stokke T. and Smeland E. B. (1995) TGF-beta 1 and cyclic AMP promote apoptosis in resting human B lymphocytes. J. Immunol. 154: 1634-1643
-
(1995)
J. Immunol.
, vol.154
, pp. 1634-1643
-
-
Lomo, J.1
Blomhoff, H.K.2
Beiske, K.3
Stokke, T.4
Smeland, E.B.5
-
175
-
-
0025895774
-
TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: Evidence in support of an autocrine hypothesis
-
175 Jennings M. T., Maciunas R. J., Carver R., Bascom C. C., Juneau P., Misulis K. et al. (1991) TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis. Int. J. Cancer 49: 129-139
-
(1991)
Int. J. Cancer
, vol.49
, pp. 129-139
-
-
Jennings, M.T.1
Maciunas, R.J.2
Carver, R.3
Bascom, C.C.4
Juneau, P.5
Misulis, K.6
-
176
-
-
0026712153
-
Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: Validity of neutralizing antibodies to block tumor growth
-
176 Ucki N., Nakazato M., Ohkawa T., Ikeda T., Amuro Y., Hada T. et al. (1992) Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim. Biophys. Acta 1137: 189-196
-
(1992)
Biochim. Biophys. Acta
, vol.1137
, pp. 189-196
-
-
Ucki, N.1
Nakazato, M.2
Ohkawa, T.3
Ikeda, T.4
Amuro, Y.5
Hada, T.6
-
177
-
-
0031698247
-
Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene
-
177 Liau L. M., Fakhrai H. and Black K. L. (1998) Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene. Neurol. Res. 20: 742-747
-
(1998)
Neurol. Res.
, vol.20
, pp. 742-747
-
-
Liau, L.M.1
Fakhrai, H.2
Black, K.L.3
-
178
-
-
0027223428
-
The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma
-
178 Jachimczak P., Bogdahn U., Schneider J., Behl C., Meixensberger J., Apfel R. et al. (1993) The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J. Neurosurg. 78: 944-951
-
(1993)
J. Neurosurg.
, vol.78
, pp. 944-951
-
-
Jachimczak, P.1
Bogdahn, U.2
Schneider, J.3
Behl, C.4
Meixensberger, J.5
Apfel, R.6
-
179
-
-
0031717878
-
Decorin gene transfer-mediated suppression of TGF-β synthesis abrogates experimental malignant glioma growth in vivo
-
179 Ständer M., Naumann U., Dumitrescu L., Heneka M., Löschmann P., Gulbins E. et al. (1998) Decorin gene transfer-mediated suppression of TGF-β synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther. 5: 1187-1194
-
(1998)
Gene Ther.
, vol.5
, pp. 1187-1194
-
-
Ständer, M.1
Naumann, U.2
Dumitrescu, L.3
Heneka, M.4
Löschmann, P.5
Gulbins, E.6
-
180
-
-
0026735230
-
Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I
-
180 Trojan J., Blossey B. K., Johnson T. R., Rudin S. D., Tykocinski M. and Ilan J. (1992) Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc. Natl. Acad. Sci. USA 89: 4874-4878
-
(1992)
Proc. Natl. Acad. Sci. USA
, vol.89
, pp. 4874-4878
-
-
Trojan, J.1
Blossey, B.K.2
Johnson, T.R.3
Rudin, S.D.4
Tykocinski, M.5
Ilan, J.6
-
181
-
-
0030889351
-
Curing rat glioblastoma: Immunotherapy or graft rejection?
-
181 Beutler A. S., Banck M. S. and Aguzzi A. (1997) Curing rat glioblastoma: immunotherapy or graft rejection? Science 276: 20-21
-
(1997)
Science
, vol.276
, pp. 20-21
-
-
Beutler, A.S.1
Banck, M.S.2
Aguzzi, A.3
-
182
-
-
0024514296
-
Prostaglandin and thromboxane synthesis by human intracranial tumors
-
182 Castelli M. G., Chiabrando C., Fanelli R., Martelli L., Butti G., Gaetani P. et al. (1989) Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res. 49: 1505-1508
-
(1989)
Cancer Res.
, vol.49
, pp. 1505-1508
-
-
Castelli, M.G.1
Chiabrando, C.2
Fanelli, R.3
Martelli, L.4
Butti, G.5
Gaetani, P.6
-
183
-
-
0025773050
-
Malignant glioma modulation of immune function: Relative contribution of different soluble factors
-
183 Couldwell W. T., Dore Duffy P., Apuzzo M. L. and Antel J. P. (1991) Malignant glioma modulation of immune function: relative contribution of different soluble factors. J. Neuroimmunol. 33: 89-96
-
(1991)
J. Neuroimmunol.
, vol.33
, pp. 89-96
-
-
Couldwell, W.T.1
Dore Duffy, P.2
Apuzzo, M.L.3
Antel, J.P.4
-
184
-
-
0020461752
-
Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells
-
184 Fontana A., Kristensen F., Dubs R., Gemsa D. and Weber E. (1982) Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J. Immunol. 129: 2413-2419
-
(1982)
J. Immunol.
, vol.129
, pp. 2413-2419
-
-
Fontana, A.1
Kristensen, F.2
Dubs, R.3
Gemsa, D.4
Weber, E.5
-
185
-
-
0025195323
-
Influence of PGE2-and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes
-
185 Kuppner M. C., Sawamura Y., Hamou M. E. and Tribolet N. de (1990) Influence of PGE2-and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes. J. Neurosurg. 72: 619-625
-
(1990)
J. Neurosurg.
, vol.72
, pp. 619-625
-
-
Kuppner, M.C.1
Sawamura, Y.2
Hamou, M.E.3
De Tribolet, N.4
-
186
-
-
0028807156
-
Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro
-
186 Hishii M., Nitta T., Ishida H., Ebato M., Kurosu A., Yagita H. et al. (1995) Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 37: 1160-1166
-
(1995)
Neurosurgery
, vol.37
, pp. 1160-1166
-
-
Hishii, M.1
Nitta, T.2
Ishida, H.3
Ebato, M.4
Kurosu, A.5
Yagita, H.6
-
187
-
-
0027998817
-
In vitro studies of cytokine-mediated interactions between malignant glioma and autologous peripheral blood mononuclear cells
-
187 Jachimezak P., Schwulera U. and Bogdahn U. (1994) In vitro studies of cytokine-mediated interactions between malignant glioma and autologous peripheral blood mononuclear cells. J. Neurosurg. 81: 579-586
-
(1994)
J. Neurosurg.
, vol.81
, pp. 579-586
-
-
Jachimezak, P.1
Schwulera, U.2
Bogdahn, U.3
-
188
-
-
0025933119
-
Monocyte tumoricidal activity and tumor necrosis factor production in patients with malignant brain tumors
-
188 Barna B. P., Rogers L. R., Thomassen M. J., Barnett G. H. and Estes M. L. (1991) Monocyte tumoricidal activity and tumor necrosis factor production in patients with malignant brain tumors. Cancer Immunol. Immunother. 33: 314-318
-
(1991)
Cancer Immunol. Immunother.
, vol.33
, pp. 314-318
-
-
Barna, B.P.1
Rogers, L.R.2
Thomassen, M.J.3
Barnett, G.H.4
Estes, M.L.5
-
189
-
-
0027935396
-
Enhanced interleukin-1 beta release and longevity of glioma-associated peripheral blood monocytes in vitro
-
189 Fries G., Perneczky A. and Kempski O. (1994) Enhanced interleukin-1 beta release and longevity of glioma-associated peripheral blood monocytes in vitro. Neurosurgery 35: 264-270
-
(1994)
Neurosurgery
, vol.35
, pp. 264-270
-
-
Fries, G.1
Perneczky, A.2
Kempski, O.3
-
190
-
-
0026322151
-
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
-
190 Bruggen P. van der, Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B. et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647
-
(1991)
Science
, vol.254
, pp. 1643-1647
-
-
Van Der Bruggen, P.1
Traversari, C.2
Chomez, P.3
Lurquin, C.4
De Plaen, E.5
Van Den Eynde, B.6
-
191
-
-
0027276474
-
The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas
-
191 Rimoldi D., Romero P. and Carrel S. (1993) The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. Int. J. Cancer 54: 527-528
-
(1993)
Int. J. Cancer
, vol.54
, pp. 527-528
-
-
Rimoldi, D.1
Romero, P.2
Carrel, S.3
-
192
-
-
0027303111
-
In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53
-
192 Houbiers J. G., Nijman H. W., Burg S. H. van der, Drijfhout J. W., Kenemans P., Velde C. J. van de et al. (1993) In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23: 2072-2077
-
(1993)
Eur. J. Immunol.
, vol.23
, pp. 2072-2077
-
-
Houbiers, J.G.1
Nijman, H.W.2
Van Der Burg, S.H.3
Drijfhout, J.W.4
Kenemans, P.5
Van De Velde, C.J.6
-
193
-
-
0028203254
-
A mouse mutant p53 product recognized by CD4 + and CD8 + t cells
-
193 Noguchi Y., Chen Y. T. and Old L. J. (1994) A mouse mutant p53 product recognized by CD4 + and CD8 + T cells. Proc. Natl. Acad. Sci. USA 91: 3171-3175
-
(1994)
Proc. Natl. Acad. Sci. USA
, vol.91
, pp. 3171-3175
-
-
Noguchi, Y.1
Chen, Y.T.2
Old, L.J.3
-
194
-
-
0021932240
-
Amplification, enhanced expression and possible rearrangement of FGF receptor gene in primary human brain tumours of glial origin
-
194 Libermann T. A., Nusbaum H. R., Razon N., Kris R., Lax I., Soreq H. et al. (1985) Amplification, enhanced expression and possible rearrangement of FGF receptor gene in primary human brain tumours of glial origin. Nature 313: 144-147
-
(1985)
Nature
, vol.313
, pp. 144-147
-
-
Libermann, T.A.1
Nusbaum, H.R.2
Razon, N.3
Kris, R.4
Lax, I.5
Soreq, H.6
-
196
-
-
0031464925
-
B7-1(CD80)-transfected human glioma cells and interleukin-12 directly stimulate allogeneic CD8 + T cells
-
196 Komata T., Tanaka R., Yamamoto K., Oda T., Ono K., Yoshida S. et al. (1997) B7-1(CD80)-transfected human glioma cells and interleukin-12 directly stimulate allogeneic CD8 + T cells. J. Immunother. 20: 256-264
-
(1997)
J. Immunother.
, vol.20
, pp. 256-264
-
-
Komata, T.1
Tanaka, R.2
Yamamoto, K.3
Oda, T.4
Ono, K.5
Yoshida, S.6
-
197
-
-
0030743966
-
Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model
-
197 Parney I. F., Petruk K. C., Zhang C., Farr Jones M., Sykes D. B. and Chang L. J. (1997) Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model. Hum. Gene Ther. 8: 1073-1085
-
(1997)
Hum. Gene Ther.
, vol.8
, pp. 1073-1085
-
-
Parney, I.F.1
Petruk, K.C.2
Zhang, C.3
Farr Jones, M.4
Sykes, D.B.5
Chang, L.J.6
-
199
-
-
0344938399
-
IL-1 beta inhibits IFN-γ-induced class II MHC expression by suppressing transcription of the class II transactivator gene
-
199 Rohn W., Tang L. P., Dong Y. and Benveniste E. N. (1999) IL-1 beta inhibits IFN-γ-induced class II MHC expression by suppressing transcription of the class II transactivator gene. J. Immunol. 162: 886-896
-
(1999)
J. Immunol.
, vol.162
, pp. 886-896
-
-
Rohn, W.1
Tang, L.P.2
Dong, Y.3
Benveniste, E.N.4
-
200
-
-
0027937745
-
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
-
200 Lowin B., Hahne M., Mattmann C. and Tschopp J. (1994) Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370: 650-652
-
(1994)
Nature
, vol.370
, pp. 650-652
-
-
Lowin, B.1
Hahne, M.2
Mattmann, C.3
Tschopp, J.4
-
201
-
-
0032435612
-
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma
-
201 Friedman H. S., McLendon R. E., Kerby T., Dugan M., Bigner S. H., Henry A. J. et al. (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J. Clin. Oncol. 16: 3851-3857
-
(1998)
J. Clin. Oncol.
, vol.16
, pp. 3851-3857
-
-
Friedman, H.S.1
McLendon, R.E.2
Kerby, T.3
Dugan, M.4
Bigner, S.H.5
Henry, A.J.6
-
202
-
-
0032008537
-
O6-methylguanine-DNA methyltransferase activity in adult gliomas: Relation to patient and tumor characteristics
-
202 Silber J. R., Bobola M. S., Ghatan S., Blank A., Kolstoe D. D. and Berger M. S. (1998) O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res. 58: 1068-1073
-
(1998)
Cancer Res.
, vol.58
, pp. 1068-1073
-
-
Silber, J.R.1
Bobola, M.S.2
Ghatan, S.3
Blank, A.4
Kolstoe, D.D.5
Berger, M.S.6
-
203
-
-
0031869758
-
Predicting response to cancer chemotherapy: The role of p53
-
203 Weller M. (1998) Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 292: 435-445
-
(1998)
Cell Tissue Res.
, vol.292
, pp. 435-445
-
-
Weller, M.1
-
204
-
-
0031705691
-
p53 and brain tumors: From gene mutations to gene therapy
-
204 Fulci G., Ishii N. and Van Meir E. G. (1998) p53 and brain tumors: from gene mutations to gene therapy. Brain Pathol. 8: 599-613
-
(1998)
Brain Pathol.
, vol.8
, pp. 599-613
-
-
Fulci, G.1
Ishii, N.2
Van Meir, E.G.3
-
205
-
-
0031689575
-
Chemosensitivity of human malignant glioma: Modulation by p53 gene transfer
-
205 Trepel M., Groseurth P., Malipiero U., Gulbins E., Dichgans J. and Weller M. (1998) Chemosensitivity of human malignant glioma: modulation by p53 gene transfer. J. Neurooncol. 39: 19-32
-
(1998)
J. Neurooncol.
, vol.39
, pp. 19-32
-
-
Trepel, M.1
Groseurth, P.2
Malipiero, U.3
Gulbins, E.4
Dichgans, J.5
Weller, M.6
-
206
-
-
0031813862
-
Suppression of human glioma growth by adenovirus-mediated Rb gene transfer
-
206 Fueyo J., Gomez Manzano C., Yung W. K., Liu T. J., Alemany R., Bruner J. M. et al. (1998) Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology 50: 1307-1315
-
(1998)
Neurology
, vol.50
, pp. 1307-1315
-
-
Fueyo, J.1
Gomez Manzano, C.2
Yung, W.K.3
Liu, T.J.4
Alemany, R.5
Bruner, J.M.6
-
207
-
-
0030070484
-
CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated
-
207 Ueki K., Ono Y., Henson J. W., Efird J. T., Deimling A. von and Louis D. N. (1996) CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 56: 150-153
-
(1996)
Cancer Res.
, vol.56
, pp. 150-153
-
-
Ueki, K.1
Ono, Y.2
Henson, J.W.3
Efird, J.T.4
Von Deimling, A.5
Louis, D.N.6
-
208
-
-
3643119742
-
The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells
-
208 Furnari F. B., Huang H. J. and Cavenee W. K. (1998) The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res. 58: 5002-5008
-
(1998)
Cancer Res.
, vol.58
, pp. 5002-5008
-
-
Furnari, F.B.1
Huang, H.J.2
Cavenee, W.K.3
-
209
-
-
0033556443
-
Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: Differential involvement of focal adhesion kinase and p130Cas
-
209 Tamura M., Gu J., Takino T. and Yamada K. M. (1999) Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res. 59: 442-449
-
(1999)
Cancer Res.
, vol.59
, pp. 442-449
-
-
Tamura, M.1
Gu, J.2
Takino, T.3
Yamada, K.M.4
-
210
-
-
0032431028
-
PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells
-
210 Li D. M. and Sun H. (1998) PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc. Natl. Acad. Sci. USA 95: 15406-15411
-
(1998)
Proc. Natl. Acad. Sci. USA
, vol.95
, pp. 15406-15411
-
-
Li, D.M.1
Sun, H.2
-
211
-
-
0032566064
-
Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas
-
211 Maier D., Zhang Z., Taylor E, Hamou M. F., Gratzl O., Van Meir E. G. et al. (1998) Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas. Oncogene 16: 3331-3335
-
(1998)
Oncogene
, vol.16
, pp. 3331-3335
-
-
Maier, D.1
Zhang, Z.2
Taylor, E.3
Hamou, M.F.4
Gratzl, O.5
Van Meir, E.G.6
-
212
-
-
0033536225
-
PTEN gene transfer in human malignant glioma: Sensitization to irradiation and CD95L-induced apoptosis
-
212 Wick W., Furnari F. B., Naumann U., Cavenee W. K. and Weller M. (1999) PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene 18: 3936-3943
-
(1999)
Oncogene
, vol.18
, pp. 3936-3943
-
-
Wick, W.1
Furnari, F.B.2
Naumann, U.3
Cavenee, W.K.4
Weller, M.5
-
213
-
-
0030979773
-
Double identity for proteins of the Bcl-2 family
-
213 Reed J. C. (1997) Double identity for proteins of the Bcl-2 family. Nature 387: 773-776
-
(1997)
Nature
, vol.387
, pp. 773-776
-
-
Reed, J.C.1
-
214
-
-
0029010631
-
Prolooncogene bcl-2 gene transfer abrogates Fas/ APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation
-
214 Weller M., Malipiero U., Aguzzi A., Reed J. C. and Fontana A. (1995) Prolooncogene bcl-2 gene transfer abrogates Fas/ APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Invest. 95: 2633-2643
-
(1995)
J. Clin. Invest.
, vol.95
, pp. 2633-2643
-
-
Weller, M.1
Malipiero, U.2
Aguzzi, A.3
Reed, J.C.4
Fontana, A.5
-
215
-
-
0030892234
-
Apoptosis by death factor
-
215 Nagata S. (1997) Apoptosis by death factor. Cell 88: 355-365
-
(1997)
Cell
, vol.88
, pp. 355-365
-
-
Nagata, S.1
-
216
-
-
0028670382
-
The role of APO-1-mediated apoptosis in the immune system
-
216 Krammer P. H., Dhein J., Walczak H., Behrmann I., Mariani S., Matiba B. et al. (1994) The role of APO-1-mediated apoptosis in the immune system. Immunol. Rev. 142: 175-191
-
(1994)
Immunol. Rev.
, vol.142
, pp. 175-191
-
-
Krammer, P.H.1
Dhein, J.2
Walczak, H.3
Behrmann, I.4
Mariani, S.5
Matiba, B.6
-
217
-
-
0027161158
-
Effect of bcl-2 on Fas antigen-mediated cell death
-
217 Itoh N., Tsujimoto Y. and Nagata S. (1993) Effect of bcl-2 on Fas antigen-mediated cell death. J. Immunol. 151: 621-627
-
(1993)
J. Immunol.
, vol.151
, pp. 621-627
-
-
Itoh, N.1
Tsujimoto, Y.2
Nagata, S.3
-
218
-
-
17444424930
-
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
-
218 Pitti R. M., Marsters S. A., Lawrence D. A., Roy M., Kischkel F. C., Dowd P. et al. (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396: 699-703
-
(1998)
Nature
, vol.396
, pp. 699-703
-
-
Pitti, R.M.1
Marsters, S.A.2
Lawrence, D.A.3
Roy, M.4
Kischkel, F.C.5
Dowd, P.6
-
219
-
-
0029840585
-
Fas ligand and immune evasion
-
219 Nagata S. (1996) Fas ligand and immune evasion. Nat. Med. 2: 1306-1307
-
(1996)
Nat. Med.
, vol.2
, pp. 1306-1307
-
-
Nagata, S.1
-
220
-
-
0030895084
-
Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?
-
220 Saas P., Walker P. R., Hahne M., Quiquerez A. L., Schnuriger V., Perrin G. et al. (1997) Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. 99: 1173-1178
-
(1997)
J. Clin. Invest.
, vol.99
, pp. 1173-1178
-
-
Saas, P.1
Walker, P.R.2
Hahne, M.3
Quiquerez, A.L.4
Schnuriger, V.5
Perrin, G.6
-
221
-
-
0030883910
-
CD9S-dependent T cell killing by glioma cells expressing CD95L: More on tumor immune escape, the CD95 counterattack, and the immune privilege of the brain
-
221 Weller M., Weinstock C., Will C., Wagenknecht B., Dichgans J., Lang F. et al. (1997) CD9S-dependent T cell killing by glioma cells expressing CD95L: more on tumor immune escape, the CD95 counterattack, and the immune privilege of the brain. Cell Physiol. Biochem. 7: 282-288
-
(1997)
Cell Physiol. Biochem.
, vol.7
, pp. 282-288
-
-
Weller, M.1
Weinstock, C.2
Will, C.3
Wagenknecht, B.4
Dichgans, J.5
Lang, F.6
-
222
-
-
0030610033
-
Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors
-
222 Gratas C., Tohma Y., Van Meir E. G., Klein M., Tenan M., Ishii N. et al. (1997) Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 7: 863-869
-
(1997)
Brain Pathol.
, vol.7
, pp. 863-869
-
-
Gratas, C.1
Tohma, Y.2
Van Meir, E.G.3
Klein, M.4
Tenan, M.5
Ishii, N.6
-
223
-
-
0032575714
-
Death receptors: Signaling and modulation
-
223 Ashkenazi A. and Dixit V. M. (1998) Death receptors: signaling and modulation. Science 281: 1305-1308
-
(1998)
Science
, vol.281
, pp. 1305-1308
-
-
Ashkenazi, A.1
Dixit, V.M.2
-
224
-
-
0031472042
-
Cell death: TRAIL and its receptors
-
224 Golstein P. (1997) Cell death: TRAIL and its receptors. CUTT. Biol. 7: R750-753
-
(1997)
CUTT. Biol.
, vol.7
-
-
Golstein, P.1
-
225
-
-
0027420929
-
Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells
-
225 Leithäuser F., Dhein J., Mechtersheimer G., Koretz K., Bruderlein S., Henne C. et al. (1993) Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest. 69: 415-429
-
(1993)
Lab. Invest.
, vol.69
, pp. 415-429
-
-
Leithäuser, F.1
Dhein, J.2
Mechtersheimer, G.3
Koretz, K.4
Bruderlein, S.5
Henne, C.6
-
226
-
-
0029985912
-
Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover
-
226 French L. E., Hahne M., Viard I., Radlgruber G., Zanone R., Becker K. et al. (1996) Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell Biol. 133: 335-343
-
(1996)
J. Cell Biol.
, vol.133
, pp. 335-343
-
-
French, L.E.1
Hahne, M.2
Viard, I.3
Radlgruber, G.4
Zanone, R.5
Becker, K.6
-
227
-
-
0028051493
-
Fas ligation triggers apoptosis in macrophages but not endothelial cells
-
227 Richardson B. C., Lalwani N. D., Johnson K. J. and Marks R. M. (1994) Fas ligation triggers apoptosis in macrophages but not endothelial cells. Eur. J. Immunol. 24: 2640-2645
-
(1994)
Eur. J. Immunol.
, vol.24
, pp. 2640-2645
-
-
Richardson, B.C.1
Lalwani, N.D.2
Johnson, K.J.3
Marks, R.M.4
-
228
-
-
0033557734
-
CD95 (Fas/Apo-1) as a receptor governing astrocyte apoptotic or inflammatory responses: A key role in brain inflammation?
-
228 Saas P., Boucraut J., Quiquerez A. L., Schnuriger V., Perrin G., Desplat-Jego S. et al. (1999) CD95 (Fas/Apo-1) as a receptor governing astrocyte apoptotic or inflammatory responses: a key role in brain inflammation? J. Immunol. 162: 2326-2333
-
(1999)
J. Immunol.
, vol.162
, pp. 2326-2333
-
-
Saas, P.1
Boucraut, J.2
Quiquerez, A.L.3
Schnuriger, V.4
Perrin, G.5
Desplat-Jego, S.6
-
229
-
-
0344258462
-
Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-alpha, or IFN-gamma
-
229 Choi C., Park J. Y., Lee J., Lim J. H., Shin E. C., Ahn Y. S. et al. (1999) Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-alpha, or IFN-gamma. J. Immunol. 162: 1889-1895
-
(1999)
J. Immunol.
, vol.162
, pp. 1889-1895
-
-
Choi, C.1
Park, J.Y.2
Lee, J.3
Lim, J.H.4
Shin, E.C.5
Ahn, Y.S.6
-
230
-
-
0028866388
-
Fas antigen expression in brains of patients with Alzheimer-type dementia
-
230 Nishimura T., Akiyama H., Yonehara S., Kondo H., Ikeda K., Kato M. et al. (1995) Fas antigen expression in brains of patients with Alzheimer-type dementia. Brain Res. 695: 137-145
-
(1995)
Brain Res.
, vol.695
, pp. 137-145
-
-
Nishimura, T.1
Akiyama, H.2
Yonehara, S.3
Kondo, H.4
Ikeda, K.5
Kato, M.6
-
231
-
-
0029960673
-
Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain
-
231 Dowling P., Shang G., Raval S., Menonna J., Cook S. and Husar W. (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J. Exp. Med. 184: 1513-1518
-
(1996)
J. Exp. Med.
, vol.184
, pp. 1513-1518
-
-
Dowling, P.1
Shang, G.2
Raval, S.3
Menonna, J.4
Cook, S.5
Husar, W.6
-
232
-
-
4243885292
-
Fas/APO-1-mediated apoptosis of human malignant glioma
-
232 Weller M., Frei K., Malipiero U., Groseurth P., Yonekawa Y., Krammer P. et al. (1995) Fas/APO-1-mediated apoptosis of human malignant glioma. Neurology 45 (Suppl. 4): 859S
-
(1995)
Neurology
, vol.45
, Issue.SUPPL. 4
-
-
Weller, M.1
Frei, K.2
Malipiero, U.3
Groseurth, P.4
Yonekawa, Y.5
Krammer, P.6
-
233
-
-
0028818019
-
Expression of Fas/APO-1 during the progression of astrocytomas
-
233 Tachibana O., Nakazawa H., Lampe J., Watanabe K., Kleihues P. and Ohgaki H. (1995) Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res. 55: 5528-5530
-
(1995)
Cancer Res.
, vol.55
, pp. 5528-5530
-
-
Tachibana, O.1
Nakazawa, H.2
Lampe, J.3
Watanabe, K.4
Kleihues, P.5
Ohgaki, H.6
-
234
-
-
0031916087
-
Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas
-
234 Tohma Y., Gratas C., Van Meir E. G., Desbaillets I., Tenan M., Tachibana O. et al. (1998) Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J. Neuropathol. Exp. Neurol. 57: 239-245
-
(1998)
J. Neuropathol. Exp. Neurol.
, vol.57
, pp. 239-245
-
-
Tohma, Y.1
Gratas, C.2
Van Meir, E.G.3
Desbaillets, I.4
Tenan, M.5
Tachibana, O.6
-
235
-
-
13344285339
-
Identification and characterization of a new member of the TNF family that induces apoptosis
-
235 Wiley S. R., Schooley K., Smolak P. J., Din W. S., Huang C. P., Nicholl J. K. et al. (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682
-
(1995)
Immunity
, vol.3
, pp. 673-682
-
-
Wiley, S.R.1
Schooley, K.2
Smolak, P.J.3
Din, W.S.4
Huang, C.P.5
Nicholl, J.K.6
-
237
-
-
0030792712
-
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
-
237 Sheridan J. P., Marsters S. A., Pitti R. M., Gurney A., Skubatch M., Baldwin D. et al. (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821
-
(1997)
Science
, vol.277
, pp. 818-821
-
-
Sheridan, J.P.1
Marsters, S.A.2
Pitti, R.M.3
Gurney, A.4
Skubatch, M.5
Baldwin, D.6
-
238
-
-
0030762815
-
An antagonist decoy receptor and a death domain-containing receptor for TRAIL
-
238 Pan G., Ni J., Wei Y. F., Yu G., Gentz R. and Dixit V. M. (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815-818
-
(1997)
Science
, vol.277
, pp. 815-818
-
-
Pan, G.1
Ni, J.2
Wei, Y.F.3
Yu, G.4
Gentz, R.5
Dixit, V.M.6
-
239
-
-
13144265771
-
A novel receptor for Apo2l/TRAIL contains a truncated death domain
-
239 Marsters S. A., Sheridan J. P., Pitti R. M., Huang A., Skubatch M., Baldwin D. et al. (1997) A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7: 1003-1006
-
(1997)
Curr. Biol.
, vol.7
, pp. 1003-1006
-
-
Marsters, S.A.1
Sheridan, J.P.2
Pitti, R.M.3
Huang, A.4
Skubatch, M.5
Baldwin, D.6
-
240
-
-
0029073752
-
Fas/APO-1 gene transfer for human malignant glioma
-
240 Weller M., Malipiero U., Rensing Ehl A., Barr P. J. and Fontana A. (1995) Fas/APO-1 gene transfer for human malignant glioma. Cancer Res. 55: 2936-2944
-
(1995)
Cancer Res.
, vol.55
, pp. 2936-2944
-
-
Weller, M.1
Malipiero, U.2
Rensing Ehl, A.3
Barr, P.J.4
Fontana, A.5
-
241
-
-
0032509754
-
Synergy of CD95 ligand and teniposide: No role of eleavable complex formation and enhanced CD95 expression
-
241 Winter S., Roth W., Dichgans J. and Weller M. (1998) Synergy of CD95 ligand and teniposide: no role of eleavable complex formation and enhanced CD95 expression. Eur. J. Pharmacol. 341: 323-328
-
(1998)
Eur. J. Pharmacol.
, vol.341
, pp. 323-328
-
-
Winter, S.1
Roth, W.2
Dichgans, J.3
Weller, M.4
-
242
-
-
0032159285
-
Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNa synthesis but not changes in CD95 or CD95L protein expression
-
242 Winter S. and Weller M. (1998) Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression. J. Pharmacol. Exp. Ther. 286: 1374-1382
-
(1998)
J. Pharmacol. Exp. Ther.
, vol.286
, pp. 1374-1382
-
-
Winter, S.1
Weller, M.2
-
243
-
-
0031588345
-
Topoisomerase-I inhibitors for human malignant glioma: Differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone
-
243 Weller M., Winter S., Schmidt C., Esser P., Fontana A., Dichgans J. et al. (1997) Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone. Int. J. Cancer 73: 707-714
-
(1997)
Int. J. Cancer
, vol.73
, pp. 707-714
-
-
Weller, M.1
Winter, S.2
Schmidt, C.3
Esser, P.4
Fontana, A.5
Dichgans, J.6
-
244
-
-
0031852453
-
Chemotherapy primes malignant glioma cells for CD95 ligand-induced apoptosis up-stream of caspase 3 activation
-
244 Hueber A., Winter S. and Weller M. (1998) Chemotherapy primes malignant glioma cells for CD95 ligand-induced apoptosis up-stream of caspase 3 activation. Eur. J. Pharmacol. 352: 111-115
-
(1998)
Eur. J. Pharmacol.
, vol.352
, pp. 111-115
-
-
Hueber, A.1
Winter, S.2
Weller, M.3
-
245
-
-
0040419494
-
Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53
-
245 Müller M., Strand S., Hug H., Heinemann E. M., Walczak H., Hofmann W. J. et al. (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99: 403-413
-
(1997)
J. Clin. Invest.
, vol.99
, pp. 403-413
-
-
Müller, M.1
Strand, S.2
Hug, H.3
Heinemann, E.M.4
Walczak, H.5
Hofmann, W.J.6
-
246
-
-
0029935682
-
Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
-
246 Friesen C., Herr I., Krammer P. H. and Debatin K. M. (1996) Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 2: 574-577
-
(1996)
Nat. Med.
, vol.2
, pp. 574-577
-
-
Friesen, C.1
Herr, I.2
Krammer, P.H.3
Debatin, K.M.4
-
247
-
-
0030752603
-
The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells
-
247 Fulda S., Sieverts H., Friesen C., Herr I. and Debatin K. M. (1997) The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 57: 3823-3829
-
(1997)
Cancer Res.
, vol.57
, pp. 3823-3829
-
-
Fulda, S.1
Sieverts, H.2
Friesen, C.3
Herr, I.4
Debatin, K.M.5
-
248
-
-
0030806351
-
Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions
-
248 Eischen C. M., Kottke T. J., Martins L. M., Basi G. S., Tung J. S., Earnshaw W. C. et al. (1997) Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 90: 935-943
-
(1997)
Blood
, vol.90
, pp. 935-943
-
-
Eischen, C.M.1
Kottke, T.J.2
Martins, L.M.3
Basi, G.S.4
Tung, J.S.5
Earnshaw, W.C.6
-
249
-
-
0030781018
-
Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way
-
249 Gamen S., Anel A., Lasierra P., Alava M. A., Martinez Lorenzo M. J., Pineiro A. et al. (1997) Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FFBS Lett. 417: 360-364
-
(1997)
FFBS Lett.
, vol.417
, pp. 360-364
-
-
Gamen, S.1
Anel, A.2
Lasierra, P.3
Alava, M.A.4
Martinez Lorenzo, M.J.5
Pineiro, A.6
-
250
-
-
0030744833
-
Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells
-
250 Villunger A., Egle A., Kos M., Hartmann B. L., Geley S., Kofler R. et al. (1997) Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res. 57: 3331-3334
-
(1997)
Cancer Res.
, vol.57
, pp. 3331-3334
-
-
Villunger, A.1
Egle, A.2
Kos, M.3
Hartmann, B.L.4
Geley, S.5
Kofler, R.6
-
251
-
-
0027291205
-
Lethal effect of the anti-fas antibody in mice
-
251 Ogasawara J., Watanabe Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y. et al. (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364: 806-809
-
(1993)
Nature
, vol.364
, pp. 806-809
-
-
Ogasawara, J.1
Watanabe Fukunaga, R.2
Adachi, M.3
Matsuzawa, A.4
Kasugai, T.5
Kitamura, Y.6
-
252
-
-
0029096804
-
Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo
-
252 Rensing Ehl A., Frei K., Flury R., Matiba B., Muriani S. M., Weller M. et al. (1995) Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Fur. J. Immunol. 25: 2253-2258
-
(1995)
Fur. J. Immunol.
, vol.25
, pp. 2253-2258
-
-
Rensing Ehl, A.1
Frei, K.2
Flury, R.3
Matiba, B.4
Muriani, S.M.5
Weller, M.6
-
254
-
-
0031042972
-
Antitumor effect of locally produced CD95 ligand
-
254 Seino K., Kayagaki N., Okumura K. and Yagita H. (1997) Antitumor effect of locally produced CD95 ligand. Nat. Med. 3: 165-170
-
(1997)
Nat. Med.
, vol.3
, pp. 165-170
-
-
Seino, K.1
Kayagaki, N.2
Okumura, K.3
Yagita, H.4
-
255
-
-
0032008535
-
Retroviral transfer of CPP32beta gene into malignant gliomas in vitro and in vivo
-
255 Kondo S., Tanaka Y., Kondo Y., Ishizaka Y., Hitomi M., Haqqi T. et al. (1998) Retroviral transfer of CPP32beta gene into malignant gliomas in vitro and in vivo. Cancer Res. 58: 962-967
-
(1998)
Cancer Res.
, vol.58
, pp. 962-967
-
-
Kondo, S.1
Tanaka, Y.2
Kondo, Y.3
Ishizaka, Y.4
Hitomi, M.5
Haqqi, T.6
-
256
-
-
0032551590
-
FADD gene therapy for malignant gliomas in vitro and in vivo
-
256 Kondo S., Ishizaka Y., Okada T., Kondo Y., Hitomi M., Tanaka Y. et al. (1998) FADD gene therapy for malignant gliomas in vitro and in vivo. Hum. Gene Ther. 9: 1599-1608
-
(1998)
Hum. Gene Ther.
, vol.9
, pp. 1599-1608
-
-
Kondo, S.1
Ishizaka, Y.2
Okada, T.3
Kondo, Y.4
Hitomi, M.5
Tanaka, Y.6
-
257
-
-
0030467622
-
Retroviral delivery and tetracycline-dependent expression of IL-1 beta-converting enzyme (ICE) in a rat glioma model provides controlled induction of apoptotic death in tumor cells
-
257 Yu J. S., Sena-Esteves M., Paulus W., Breakefield X. O. and Reeves S. A. (1996) Retroviral delivery and tetracycline-dependent expression of IL-1 beta-converting enzyme (ICE) in a rat glioma model provides controlled induction of apoptotic death in tumor cells. Cancer Res. 56: 5423-5427
-
(1996)
Cancer Res.
, vol.56
, pp. 5423-5427
-
-
Yu, J.S.1
Sena-Esteves, M.2
Paulus, W.3
Breakefield, X.O.4
Reeves, S.A.5
-
258
-
-
0032079348
-
APO2 ligand: A novel lethal weapon against malignant glioma?
-
258 Rieger J., Naumann U., Glaser T., Ashkenazi A. and Weller M. (1998) APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett. 427: 124-128
-
(1998)
FEBS Lett.
, vol.427
, pp. 124-128
-
-
Rieger, J.1
Naumann, U.2
Glaser, T.3
Ashkenazi, A.4
Weller, M.5
-
259
-
-
9844225051
-
Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies
-
259 Snell V., Clodi K., Zhao S., Goodwin R., Thomas E. K., Morris S. W. et al. (1997) Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br. J. Haematol. 99: 618-624
-
(1997)
Br. J. Haematol.
, vol.99
, pp. 618-624
-
-
Snell, V.1
Clodi, K.2
Zhao, S.3
Goodwin, R.4
Thomas, E.K.5
Morris, S.W.6
-
260
-
-
0032169208
-
TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells
-
260 Thomas W. D. and Hersey P. (1998) TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J. Immunol. 161: 2195-2200
-
(1998)
J. Immunol.
, vol.161
, pp. 2195-2200
-
-
Thomas, W.D.1
Hersey, P.2
-
261
-
-
0032530612
-
Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
-
261 Griffith T. S., Chin W. A., Jackson G. C., Lynch D. H. and Kubin M. Z. (1998) Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161: 2833-2840
-
(1998)
J. Immunol.
, vol.161
, pp. 2833-2840
-
-
Griffith, T.S.1
Chin, W.A.2
Jackson, G.C.3
Lynch, D.H.4
Kubin, M.Z.5
-
262
-
-
0030943324
-
Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells
-
262 Mariani S. M., Matiba B., Armandola E. A. and Krammer P. H. (1997) Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J. Cell Biol. 137: 221-229
-
(1997)
J. Cell Biol.
, vol.137
, pp. 221-229
-
-
Mariani, S.M.1
Matiba, B.2
Armandola, E.A.3
Krammer, P.H.4
-
263
-
-
17544367410
-
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
-
263 Pitti R. M., Marsters S. A., Ruppert S., Donahue C. J., Moore A. and Ashkenazi A. (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271: 12687-12690
-
(1996)
J. Biol. Chem.
, vol.271
, pp. 12687-12690
-
-
Pitti, R.M.1
Marsters, S.A.2
Ruppert, S.3
Donahue, C.J.4
Moore, A.5
Ashkenazi, A.6
-
264
-
-
0032929520
-
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
-
264 Walczak H., Miller R. E., Ariail K., Gliniak B., Griffith T. S., Kubin M. et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5: 157-163
-
(1999)
Nat. Med.
, vol.5
, pp. 157-163
-
-
Walczak, H.1
Miller, R.E.2
Ariail, K.3
Gliniak, B.4
Griffith, T.S.5
Kubin, M.6
|